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Structure Based Drug Design is an emerging tool employed in industry as well as 
academia in the design and discovery of therapeutically relevant molecules.  The 
enzyme S-Adenosylmethionine decarboxylase (AdoMetDC) is a critical enzyme in the 
polyamine biosynthetic pathway and an attractive target for design of anti-cancer and 
anti-proliferative compounds.  The polyamines putrescine, spermidine and sperimine 
are ubiquitous aliphatic cations essential for cell growth, differentiation, and 
proliferation.  The crystal structure of human, potato and bacterial AdoMetDC have 
been determined previously.  The crystal structure of human AdoMetDC with S-
adenosylmethionine methyl ester (MeAdoMet) and putrescine bound provided insights 
into the interactions of the substrate and putrescine with the enzyme.  It is well known 
that putrescine activates the autoprocessing and decarboxylation of human 
AdoMetDC.  To understand the structural basis of the activation, crystal structures of 
the wild type enzyme and the D174N, E178Q, and E256Q mutants were obtained in 
the putrescine free form.  Putrescine was added to the E178Q and E256Q mutants and 
the crystal structures obtained.  The crystal structures of the putrescine free mutants 
with MeAdoMet bound were also obtained.  A comparison of the crystal structures 
reveals the details of putrescine activation of Human AdoMetDC.  Based on the 
structural information of the active site and MeAdoMet binding interactions, a series 
of compounds were synthesized.  The crystal structure of human AdoMetDC with a 
 member of each of the series was obtained.  The structures coupled to biochemical 
results and quantum chemical calculations revealed details about the substrate 
specificity of AdoMetDC.  The ligands were bound to AdoMetDC with the adenine 
base in the higher energy syn conformation.  A series of compounds with substitutions 
at the C8 position of the adenine base were obtained.  These compounds turned out to 
be more potent inhibitors than the unsubstituted parent compounds.  The crystal 
structure of processed form of AdoMetDC from Thermotoga maritima and complexed 
to MeAdoMet and 5’-Deoxy-5’-dimethyl thioadenosine (MMTA) were also obtained.  
The conservation of the binding mode of ligands in prokaryotes suggests the extension 
of inhibitors of human AdoMetDC to other therapeutically relevant species. 
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CHAPTER 1 
STRUCTURAL BIOLOGY IN DRUG DESIGN 
Section 1.1. Structural Biology 
Structural biology studies biological processes from a structural view point.  
The structural details of the molecule of interest can be obtained by numerous methods 
such as X-ray crystallography, nuclear magnetic resonance spectroscopy (NMR), 
electron microscopy, laser spectroscopy, and circular dichrosim.  X-ray 
crystallography is a powerful method used to obtain the atomic position of all atoms in 
the molecule of interest when arranged in the form of a crystal lattice.  This method is 
routinely used to study the structure of molecules varying from small inorganic salts to 
large macromolecular assemblies comprising of proteins, nucleic acids etc.  X-ray 
crystallography is currently the most accurate tool in determining the atomic 
coordinates of macromoleucles.  The structural information of biologically relevant 
macromolecules aids in understanding phenomenon such as catalysis, binding, 
structure, signaling and transport. 
 Determination of structure by X-ray crystallography primarily involves the 
processes of (1) growing 3-D crystals of macromolecule of interest (2) shooting a 
focused beam of X-rays through the crystal and obtaining a diffraction pattern (3) 
obtaining the electron density of the macromolecule using various phasing techniques 
and (4) building the model of the macromolecule based on the electron density maps 
and refinement of the model.  Crystals of macromolecules are usually obtained by 
incubating pure and homogenous macromolecule with suitable precipitating agents.  
The electron density of the macromolecule is a Fourier transform involving the 
intensity of spots on the diffraction pattern and the phase of each reflection.  The 
phase value of the each reflection cannot be measured experimentally and hence has to 
be inferred indirectly.  Many methods have been developed to solve the “phase 
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problem”.  Multiple isomorphous replacement (MIR) involves soaking of a heavy 
atom into the protein crystals.  The change in scattering upon addition of heavy atom 
is analyzed for phase determination.  The most powerful technique for solving the 
phase problem is multi-wavelength anomalous diffraction (MAD).  The anomalous 
diffraction of atoms is wavelength dependant and is carefully measured by collecting 
data at two different wavelengths.  Single-wavelength anomalous diffraction (SAD) 
phasing technique is routinely used to obtain the phase information. For this 
technique, the methionine residues in the protein are replaced with selenomethionine, 
which acts as a heavy atom.  Molecular replacement is the widely used phasing 
method where the initial phases of the model are obtained from the structure of a 
homologous protein with sufficient sequence identity.  Direct methods is a powerful 
phasing tool suitable for small molecule structures or with high resolution data.  This 
method looks for statistical relationships between sets of structure factors and 
estimates the phase values for those reflections. 
Section 1.2. Structure based drug design 
The determination of 3-D structure of macromolecules of therapeutic interest 
has always been a major research for industry as well as academia.  In most of the 
cases, the structure would reveal the ligand binding site, which could be used for 
rational design of molecules with better potency (1, 2).  More recently, virtual 
screening programs perform screening of libraries of millions of compounds to the 
active site to obtain a lead compound for further development.  The virtual screening 
process is an effective way to obtain novel lead compounds and reduce drug discovery 
costs.  The lead compounds are tested using biochemical methods for potency and 
promising candidates are developed further.  The development of HIV protease 
inhibitors Nelfinavir and Amprenavir and the influenza drug Relenza have been aided 
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by structural studies (2).  The drugs Captopril, Dorzolamide, Zanamivir are a few 
examples that have been rationally developed from a structural viewpoint (3, 4). 
Structure based drug design requires that targets have an experimentally 
determined crystal structure to high accuracy.  However, there are a lot of targets that 
do not have an experimentally determined crystal structure.  In those cases, homology 
modeling provides reasonably accurate structural information of macromolecules 
tough to crystallize (5, 6).  In many cases, the structural information from homology 
modeling has been vital in making key changes to the targets for successful 
crystallization.  As of now more than 40 drugs designed through structural means have 
entered clinical trials.  As a result, the use of structure in drug discovery is gaining 
more importance in recent times. 
Section 1.3. Polyamine biosynthesis and targets 
The polyamines putrescine, spermidine and spermine are simple aliphatic 
cations implicated in cell growth and proliferation (7, 8).  At physiological conditions, 
the polyamines are positively charged with the positive charges separated from each 
other by the aliphatic carbon chain.  The polyamines are known to bind to the negative 
charged DNA, RNA and nucleic acids (9).  They are also known to maintain 
chromatin conformation and regulate specific gene expression (10-12).  In addition, 
polyamines are also implicated in ion-channel regulation, membrane stability and free 
radical scavenging (13, 14).  Elevated levels of polyamines are found in rapidly 
proliferative cells, which make the polyamine biosynthetic pathway an attractive target 
for antiproliferative diseases and cancer chemotheraphy. 
The polyamine levels in the cells are maintained by the regulation of the 
biosynthetic enzymes, catabolic enzymes and transport in/out of the cellular 
membrane.  The polyamine biosynthetic pathway has two separate branches, the 
products of which are used in the production of all the polyamines (Figure 1.1).  In the 
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first branch of the pathway, putrescine is produced by the decarboxylation of ornithine 
by ornithine decarboxylase (ODC).  In plants, an alternate pathway also produces 
putrescine.  The amino acid arginine is decarboxylated to agmatine by arginine 
decarboxylase.  Agmatine is hydrolyzed to putrescine by agmatine ureohydrolase.  In 
the second branch of the pathway, S-adenosylmethionine (AdoMet) is decarboxylated 
to decarboxylated S-adenosylmethionine (dcAdoMet) by S-adenosylmethionine 
decarboxylase (AdoMetDC).  The aminopropyl group from dcAdoMet is transferred 
to putrescine to form spermidine and in the next step the aminopropyl group is 
transferred to spermidine to form spermine.  These transfer reactions are catalyzed by 
spermidine synthase and spermine synthase respectively.  In the catabolic pathway, the 
joint action of the enzymes spermidine/spermine N1-acetyltransferase and polyamine 
oxidase convert spermine to spermidine and spermidine to putrescine in each step 
respectively. 
The inhibitors to the polyamine biosynthetic pathway and the activators of the 
catabolic pathway have shown promise as antiproliferative agents.  The biggest 
success of the inhibitors of the polyamine pathway is α-difluoromethylornithine 
(DFMO), an inhibitor of ODC that is approved by FDA for the treatment of African 
sleeping sickness caused by the parasite Trypanasoma brucei gambiense.  DFMO has 
also been a subject of various clinical trials as a chemopreventive agent.  The 
inhibitors of AdoMetDC methylglyoxalbis(guanylhydrazone) (MGBG) and 4-
amidinoindan-1-one-2´-amidinohydrazone (CGP48664A) have been a subject various 
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Figure 1.1 Overview of the polyamine biosynthetic and catabolic pathway 
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clinical trials.  The compounds N1,N11-di(ethyl)norspermine (BE-3-3-3) and an 
unsaturated variant of N1,N12-di(ethyl)spermine (CGC-11047) are polyamine analogs 
that are inducers of SSAT and spermine oxidase.  These compounds are currently in 
Phase II clinical trials in multiple cancers.  The compounds mentioned above provide 
the proof of principle that the inhibitors of the polyamine pathway have potential 
therapeutic applications. 
Section 1.4. S-Adenosylmethionine Decarboxylase 
Decarboxylation reactions in enzymes usually depend on a pyridoxal-5´-
phosphate (PLP) or a pyruvoyl group for the reaction.  AdoMetDC belongs to a small 
class of enzymes that depend on a pyruvoyl group for the decarboxylation process.  
Other examples of pyruvoyl group dependant decarboxylases are histidine 
decarboxylase and aspartate decarboxylase respectively (15, 16). 
The pyruvoyl group in AdoMetDC is generated from a serine residue in a self-
cleavage reaction.  In humans, the processing reaction happens spontaneously and 
there might be other factors involved for processing in different species.  The 
mechanism of autoprocessing in human AdoMetDC is shown in Figure 1.2.  The 
cleavage occurs between the residues Glu67 – Ser 68.  The backbone of the serine 
residue attacks the adjacent carbonyl carbon of Glu67 to generate a five-member ring 
oxyoxazolidine intermediate.  The intermediate collapses to form an ester 
intermediate.  The basic residue His243 abstracts a proton from the Cα carbon of 
Ser68 resulting in the cleavage of the ester intermediate to two chains.  The subunit 
containing the N-terminal part of the uncleaved chain is called the β subunit and the 
subunit containing the C-terminal part is called the α subunit.  The N-terminus of the 
α subunit has a newly formed dehydroalanine residue that is tautomerized to form an 
imine, which is further hydrolyzed to form the pyruvoyl group. 
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The pyruvoyl group acts as a cofactor in the decarboxylation process.  The 
substrate AdoMet binds to the enzyme by making a Schiff base to the active site 
puruvoyl group (Figure1.3).  The decarboxylation reaction proceeds with the pair of 
electrons from the leaving group delocalized into the pyruvoyl group.  The acidic 
residue Cys82 protonates the Cα carbon of the substrate to generate the imine 
intermediate.  The imine is further hydrolyzed to release the product dcAdoMet and 
regenerate the pyruvoyl group for further rounds of catalysis.  It has also been 
observed that the incorrect protonation (on the pyruvoyl group) of the intermediate 
would result in the transamination of the pyruvoyl group resulting in a dead enzyme.  
Activity assays of human AdoMetDC have indicated that on an average, the enzyme 
performs 4-5 turnover reactions before being transaminated (17). 
The polyamine putrescine is known to regulate the activity of AdoMetDC by 
affecting the rates of autoprocessing and decarboxylation respectively.  However, the 
effect of putrescine on AdoMetDC are species specific.  Putrescine activates the 
autoprocessing reactions in humans.  Putrescine activates the decarboxylation reaction 
in humans, Trypanosoma brucei, Trypanosoma cruzi, and Caenorhabditis elegans.  In 
Neurospora crassa, putrescine is essential for the decarboxylation but there is no 
effect on the processing reaction (18-21). 
The crystal structure of human AdoMetDC with the methyl ester of AdoMet 
(MeAdoMet) and putrescine bound has been determined previously (22).  The crystal 
structure reveals the active site and the binding pocket of putrescine in the enzyme.  
Putrescine binds 16 – 20 Å from the active site (Figure 1.4) and makes extensive 
interactions with the enzyme.  Human AdoMetDC exists as a dimer and biochemical 
studies reveal positive cooperativity in putrescine and substrate binding to the dimeric 
form of the enzyme (Figure 1.5). 
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Figure 1.2. Mechanism of pyruvoyl group formation in AdoMetDC. 
 
 
Figure 1.3. Mechanism of decarboxylation of AdoMetDC. 
The crystal structure of human AdoMetDC provides an opportunity to 
investigate the regulation of the enzyme and rationally design inhibitors to the active 
site.  The subsequent chapters 2-4 describe insights obtained by X-ray crystallography, 
biochemical analysis, and molecular modeling into regulation, substrate specificity, 
and inhibitor design of human AdoMetDC respectively.  Chapter 5 describes the 
structural details of processing and complex formation in Thermotoga maritima 
AdoMetDC. 
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Figure 1.4. Monomeric form of processed human AdoMetDC.  The α and β subunits 
are colored brown and yellow respectively.  Putrescine and MeAdoMet are shown as 
sticks. 
 
Figure 1.5. Dimeric form of human AdoMetDC viewing down the 2-fold axis.  
Putrescine and MeAdoMet are shown in ball and stick. 
  10 
Section 1.5. Acknowledgements 
The material in the following chapters focuses on the structural aspects of a 
collaborative project comprising of five research groups on the design of AdoMetDC 
inhibitors.  The biochemical analysis was done in Prof. Anthony Pegg’s laboratory in 
the Milton S. Hershey Medical Center of the Pennsylvania State University.  The 
synthesis of the inhibitors was done in the laboratory of Prof. John A. Secrist III at the 
Southern Research Institute.  The molecular modeling is supervised by Prof. Wayne C. 
Guida of the H. Lee Moffitt Cancer Center & Research Institute.  Dr. William Waud 
from the Southern Research Institute supervises the in vivo cytotoxicity, growth and 
polyamine assays as well as the effect of AdoMetDC inhibitors on tumours in mice.  
  11 
REFERENCES 
1. Whittle, P. J., and Blundell, T. L. (1994) Protein structure--based drug design, 
Annu Rev Biophys Biomol Struct 23, 349-375. 
2. Blundell, T. L., Sibanda, B. L., Montalvao, R. W., Brewerton, S., Chelliah, V., 
Worth, C. L., Harmer, N. J., Davies, O., and Burke, D. (2006) Structural 
biology and bioinformatics in drug design: opportunities and challenges for 
target identification and lead discovery, Philos Trans R Soc Lond B Biol Sci 
361, 413-423. 
3. Babine, R. E., and Abdel-Meguid, S. S., (Eds.) (2004) Protein Crystallography 
in Drug Discovery, Vol. 20, WILEY-VCH Verlag GmbH & Co. KGaA. 
4. Flower, D. R., (Ed.) (2002) Drug Design: Cutting Edge Approaches, The 
Royal Society of Chemistry. 
5. Eswar, N., Marti-Renom, M. A., Webb, B., Madhusudhan, M. S., Eramian, D., 
Shen, M., Pieper, U., and Sali, A. (2007) Comparative Protein 
StructureModeling with MODELLER, in Current Protocols in Protein 
Science, pp 2.9.1-2.9.31, Wiley, John & Sons, Inc. 
6. Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by 
satisfaction of spatial restraints, J. Mol. Biol. 234, 779-815. 
7. Casero, R. A., Jr., and Marton, L. J. (2007) Targeting polyamine metabolism 
and function in cancer and other hyperproliferative diseases, Nat Rev Drug 
Discov 6, 373-390. 
8. Gerner, E. W., and Meyskens, F. L., Jr. (2004) Polyamines and cancer: old 
molecules, new understanding, Nat Rev Cancer 4, 781-792. 
9. Feuerstein, B. G., Williams, L. D., Basu, H. S., and Marton, L. J. (1991) 
Implications and concepts of polyamine-nucleic acid interactions, J Cell 
Biochem 46, 37-47. 
  12 
10. Frydman, B., Westler, W. M., and Samejima, K. (1996) Spermine Binds in 
Solution to the TpsiC Loop of tRNA(Phe): Evidence from a 750 MHz (1)H-
NMR Analysis, J Org Chem 61, 2588-2589. 
11. Frydman, L., Rossomando, P. C., Frydman, V., Fernandez, C. O., Frydman, B., 
and Samejima, K. (1992) Interactions between natural polyamines and tRNA: 
an 15N NMR analysis, Proc Natl Acad Sci U S A 89, 9186-9190. 
12. Hobbs, C. A., Paul, B. A., and Gilmour, S. K. (2003) Elevated levels of 
polyamines alter chromatin in murine skin and tumors without global changes 
in nucleosome acetylation, Exp Cell Res 290, 427-436. 
13. Ha, H. C., Sirisoma, N. S., Kuppusamy, P., Zweier, J. L., Woster, P. M., and 
Casero, R. A., Jr. (1998) The natural polyamine spermine functions directly as 
a free radical scavenger, Proc Natl Acad Sci U S A 95, 11140-11145. 
14. Kurata, H. T., Marton, L. J., and Nichols, C. G. (2006) The polyamine binding 
site in inward rectifier K+ channels, J Gen Physiol 127, 467-480. 
15. Gallagher, T., Rozwarski, D. A., Ernst, S. R., and Hackert, M. L. (1993) 
Refined structure of the pyruvoyl-dependent histidine decarboxylase from 
Lactobacillus 30a, J Mol Biol 230, 516-528. 
16. Albert, A., Dhanaraj, V., Genschel, U., Khan, G., Ramjee, M. K., Pulido, R., 
Sibanda, B. L., von Delft, F., Witty, M., Blundell, T. L., Smith, A. G., and 
Abell, C. (1998) Crystal structure of aspartate decarboxylase at 2.2 Å 
resolution provides evidence for an ester in protein self-processing, Nat. Struct. 
Biol. 5, 289-293. 
17. Xiong, H., Stanley, B. A., and Pegg, A. E. (1999) Role of cysteine-82 in the 
catalytic mechanism of human S-adenosylmethionine decarboxylase, 
Biochemistry 38, 2462-2470. 
  13 
18. Beswick, T. C., Willert, E. K., and Phillips, M. A. (2006) Mechanisms of 
allosteric regulation of Trypanosoma cruzi S-adenosylmethionine 
decarboxylase, Biochemistry 45, 7797-7807. 
19. Ndjonka, D., Da'dara, A., Walter, R. D., and Luersen, K. (2003) 
Caenorhabditis elegans S-adenosylmethionine decarboxylase is highly 
stimulated by putrescine but exhibits a low specificity for activator binding, 
Biol Chem 384, 83-91. 
20. Ekstrom, J. L., Tolbert, W. D., Xiong, H., Pegg, A. E., and Ealick, S. E. (2001) 
Structure of a human S-adenosylmethionine decarboxylase self-processing 
ester intermediate and mechanism of putrescine stimulation  of processing as 
revealed by the H243A mutant., Biochemistry 40, 9495-9504. 
21. Willert, E. K., Fitzpatrick, R., and Phillips, M. A. (2007) Allosteric regulation 
of an essential trypanosome polyamine biosynthetic enzyme by a catalytically 
dead homolog, Proc Natl Acad Sci U S A 104, 8275-8280. 
22. Tolbert, D. W., Ekstrom, J. L., Mathews, I. I., Secrist, J. A. I., Kapoor, P., 
Pegg, A. E., and Ealick, S. E. (2001) The structural basis for substrate 
specificity and inhibition of human S-adenosylmethionine decarboxylase, 
Biochemistry 40, 9484-9494. 
 
 
  14 
CHAPTER 2 
STRUCTURAL BASIS FOR PUTRESCINE ACTIVATION OF HUMAN S-
ADENOSYLMETHIONINE DECARBOXYLASE1 
Section 2.1. Introduction 
S-Adenosylmethionine decarboxylase (AdoMetDC) is a critical enzyme in the 
polyamine biosynthetic pathway (1, 2) and depends on a pyruvoyl group for the 
decarboxylation reaction (3-5).  It is synthesized as a proenzyme that undergoes an 
apparent autocatalytic processing reaction to generate the pyruvoyl group from an 
internal serine residue.  The enzyme converts S-adenosylmethionine (AdoMet) to S-
adenosyl-5´-(3-methylthiopropylamine) (dcAdoMet).  The propylamine group from 
the product is transferred to putrescine to form spermidine, or spermidine to form 
spermine.  Putrescine is generated by the decarboxylation of ornithine by ornithine 
decarboxylase (ODC).  Polyamine levels are highly regulated in the cell and are 
closely linked to normal cell growth and division.  Both ODC and AdoMetDC are 
regulated through multiple mechanisms, catalyze reactions in the earlier stages of 
polyamine biosynthesis, and their reaction products are committed to polyamine 
biosynthesis.  Consequently, these enzymes are the focus of inhibitor design, for both 
anticancer and antiparasitic agents (6, 7).  α-Difluoromethylornithine is a suicide 
inhibitor of ODC and is approved by the Food and Drug Administration for the 
treatment of African sleeping sickness.  Two inhibitors of AdoMetDC, methylglyoxal 
bis(guanylhydrazone) and 4-amidinoindan-1-one-2´-amidinohydrazone 
(CGP48664A), have been the subject of several clinical trials (8-16).  Although 
neither compound is approved for clinical use, the polyamine biosynthetic pathway 
remains an attractive target for both cancer and antiparasitic chemotherapy. 
                                                
1 Reproduced with permission from Bale S, Lopez MM, Makhatadze G; Fang QI; Pegg AE, and Ealick 
SE. (2008). Biochemistry 47:13404-13417. Copyright 2008 American Chemical Society 
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All AdoMetDCs currently characterized are pyruvoyl enzymes but they can be 
divided into two classes.  Class 1 enzymes are present in bacteria and archaea and 
class 2 enzymes are present in eukaryotes (5, 17).  The human AdoMetDC proenzyme 
contains 334 amino acid residues.  The processing reaction generates the α- (67 amino 
acids) and β-subunits (266 amino acids) with the pyruvoyl group at the N-terminus of 
the β-subunit (18).  Only a small fraction of the total AdoMet pool is in the 
decarboxylated form and AdoMetDC activity is very highly regulated according to the 
need for polyamine synthesis (3, 19, 20).  An important part of this regulation in 
mammalian cells and some other eukaryotes with class 2 AdoMetDCs, but not in 
plants, is the activation of the enzyme by putrescine (3, 19-21).  Activation of the 
mammalian enzyme occurs at two stages: the rate of processing of the proenzyme is 
stimulated and the decarboxylase activity is increased in the presence of putrescine 
(22, 23).  These factors provide a link between the availability of putrescine and the 
production of dcAdoMet, which is the other substrate of spermidine synthase.  This 
allows the very efficient conversion of putrescine into spermidine without increasing 
the steady state pool of dcAdoMet. Mammalian cells therefore have spermidine 
content greatly in excess of putrescine and c.1-2% of the AdoMet is in the form of 
dcAdoMet (20, 24, 25).  AdoMetDCs from fungi and several protozoal parasites have 
also been shown to be activated by putrescine (20, 22, 26, 27), but this activation may 
occur only at the level of the stimulation of activity (28, 29). 
Structural studies of human AdoMetDC have indicated that the functional form 
of human AdoMetDC is an (αβ)2 dimer with one active site and one pyruvoyl cofactor 
per protomer (23, 30, 31).  The putrescine binding site is located between two central 
β-sheets of the enzyme, away from the active site and near the dimer interface (Figure 
2.1 A).  One end of putrescine is directly hydrogen bonded to Asp174, Glu15 and  
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Figure 2.1. Putrescine binding site of human AdoMetDC. (A) Ribbon diagram 
of AdoMetDC showing the putrescine binding site and the active site with MeAdoMet 
bound (from pdb 1I7B).  (B) Stereoview of interactions of putrescine with the enzyme. 
Putrescine carbon atoms are colored green. Water molecules are shown as red spheres 
and hydrogen bonds are shown as dashed lines. 
 
Thr176.  The other end is hydrogen bonded through water molecules to Glu178, 
Glu15, Glu256 and Ser113.  The aliphatic chain of putrescine stacks against Phe285 
and Phe111 (Figure 2.1 B). The putrescine molecule is linked to the active site by 
several buried charged residues.  Mutations of residues in the putrescine binding site 
modulate the effects of putrescine (32).  Studies using site-directed mutagenesis of the 
human and T. cruzi AdoMetDCs have identified multiple residues whose alteration 
abolished the activation (22, 29, 32-34).  These include Asp174 in the human enzyme, 
which is conserved in all the known putrescine-stimulated AdoMetDCs and is not 
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present in other class 2 AdoMetDCs such as those from plants, which are not 
putrescine activated (33, 35).  
Apart from these studies, there is virtually no information on the binding of 
putrescine to human AdoMetDC or the changes brought about by this binding.  To 
obtain further insights into the mechanism of putrescine activation, we undertook 
structural studies of human AdoMetDC and putrescine binding mutants D174N, 
E178Q and E256Q, with (+Put) and without (-Put) bound putrescine.  We have also 
studied the biochemical properties of the putrescine free enzymes using UV-CD 
spectroscopy, analytical ultracentrifugation and isothermal titration calorimetry (ITC).  
The crystal structures showed no global structural changes but revealed a local 
rearrangement of four aromatic residues near the putrescine binding site, Phe285, 
Phe315, Tyr318 and Phe320, and a conformational change in the loop 312-320.  
Biophysical studies confirmed one putrescine binding site per protomer and showed 
positive cooperativity between the two binding sites within the dimer.  Additionally, 
the D174N mutant did not bind putrescine and the E178Q and E256Q mutants bind 
putrescine weakly with no cooperativity.  Our findings demonstrate that putrescine 
activates AdoMetDC primarily through positioning of active site residues and 
electrostatic effects relayed to the active site largely through hydrogen bonding. 
Section 2.2. Materials and Methods 
Cloning and Expression.  The constructs for expression of human AdoMetDC 
and mutants were modified from those described previously  (18, 32-34) to place the 
(His)6 tag at the carboxyl end of the protein replacing the C-terminal –QQQQQS 
sequence. Briefly, primers 5'-
d(ATTAAAGAGGAGAAATTAACTATGGAAGCTGCACATTT-TTTC)-3' with a 
Bser I site (underlined) and 5'-(GTGGTGGGATTCACTCTGCTGTTG-TTGCTG)-3' 
with a BamH I site (underlined) were used as the sense and antisense primers in a PCR 
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reaction using pQE-SAMDC as a template.  The product was digested with Bser I and 
BamH I and ligated into plasmid pQE-C145S (36), which encodes the C-terminal 
(His)6–tag, that had been digested with the same enzymes.  E.coli strain BL21(DE3) 
containing the AdoMetDC wild type plasmid or plasmid for the mutant proteins was 
grown at 30 °C overnight in a 2 x YT media containing 100 mg/mL ampicillin.  The 
protein expression was induced by addition of 1 mM isopropyl-1-thio-β-D-
galactopyranoside.  Cells were harvested after 4 h and resuspended in 50 mM sodium 
phosphate pH 8.0, 200 mM NaCl, 2.5 mM putrescine and 0.1 mM 
phenylmethylsulphonyl fluoride.  The cells were lysed using a French pressure cell.  
The wild type AdoMetDC and mutants were purified using a Ni-NTA (Qiagen) 
affinity column under native conditions in the presence of 2.5 mM putrescine.  
Fractions containing the desired protein were combined and concentrated by 
ammonium sulfate precipitation (80%).  The pellet was dissolved and dialyzed against 
50 mM phosphate, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA) and 
1 mM tris(2-carboxyethyl)phosphine (TCEP) and loaded onto a Sephacryl S-200 HR 
equilibrated in the same buffer and connected to an AKTA (Pharmacia) 
chromatography system.  The eluted pure protein was concentrated by ammonium 
sulfate precipitation (80%), dissolved and dialyzed against 50 mM sodium phosphate 
pH 7.5, 1 mM TCEP, and 1 mM EDTA.  The concentrated protein was kept at –80 °C.  
The purified protein correctly processed into a 31 kDa α subunit and a 7.5 kDa β 
subunit as judged by SDS-PAGE electrophoresis.  The protein concentration was 
calculated spectrophotometrically using the extinction coefficient ε280 = 39,400 M-1 cm-
1.  Corrections for light scattering were taken into account (37). 
CD spectroscopy.  The CD experiments were performed using a Jasco J-715 
automatic recording spectrapolarimeter.  Spectra were recorded at 20 °C in 10 mM 
phosphate pH 7.5, 0.2 mM EDTA and 0.2 mM TCEP in the absence and presence of 
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putrescine.  Near-UV CD spectra were recorded in a 1 cm rectangular quartz cell.  The 
protein concentration was 15 µM.  The Far-UV CD spectra were recorded in a 1 mm 
cylindrical quartz cell.  The protein concentration was 2.5 µM.  The putrescine 
concentration was 4 fold higher than the wild type or 40-fold higher than the variant 
proteins to ensure that the proteins were saturated with putrescine.  The molar 
ellipticity,  [Θ], was calculated as: 
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where Mw is the mean molecular mass of amino acid residues in AdoMetDC (115 
Da), c is the protein concentration in mg/ml and l is the optical pathlength in 
centimeters. 
Analytical Ultracentrifugation.  Equilibrium sedimentation experiments were 
performed using a Beckman XL-A analytical ultracentrifuge with an AN-60Ti rotor, 
operating at 4 °C.  Samples were loaded into two-sector cells and spun at three 
different speeds (12,000, 15,000 and 20,000 rpm).  The absorbance at 280 nm, A, was 
recorded as a function of the radial position, r.  Equilibrium was considered to be 
attained when replicate scans separated by 6 h were indistinguishable.  The data sets 
for each protein were globally fitted according to a model in which single species are 
present in solution: 
!!
"
#
$$
%
&
''(
''
('
'+=
2
22
)1(
2
))((
exp
)*+
TR
rrM
AIA
o
o
 (2) 
where I is the baseline offset constant, M is the molecular weight of the species 
present in solution, ν is the partial specific volume (0.749 cm3/g) calculated as 
described in (38), ω is the angular velocity, R is the gas constant in erg/(mol•K), T is 
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the temperature in Kelvin and ρ is the density of the solvent (1 g/cm3).  The goodness 
of the fit was assessed by the quality of the residuals. 
Isothermal Titration Calorimetry.  The ITC experiments were performed using 
a VP-ITC titration microcalorimeter (MicroCal, Inc.).  The procedure for these 
experiments has been described previously (39).  In brief, the experiments were 
performed by injecting 3-10 µl of putrescine with concentrations ranging between 0.7 
and 16 mM into the sample cell containing the protein solution.  The protein 
concentration varied between 12 and 87 µM, depending on the magnitude of the heat 
effects observed.  The buffer used was 50 mM phosphate pH 7.5, 1 mM EDTA and 1 
mM TCEP.  Dilution effects were taken into account by injecting the putrescine 
solution into the buffer.  The heat of the reaction after each injection, qi, was obtained 
by integrating the peak after the injection using the ORIGIN software provided by the 
manufacturer.  The binding isotherms were fitted to a single set of sites (as described 
previously, (40)), model 1 in which 2 molecules of putrescine bind to the dimeric 
protein according to scheme 1 as shown below. 
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+!+=  and [M]T is the total protein concentration expressed per 
monomer, [L]T is the total putrescine concentration, n is the stoichiometry of the interaction, 
ΔH is the enthalpy of binding  and K is the equilibrium constant. 
Putrescine binding to wild type AdoMetDC was also fitted according to model 
2 (scheme 2 shown below) (41). 
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The heat of the reaction expressed per mol of protein relates to the thermodynamic 
parameters as follows: 
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ΔH1 and ΔH2 are the enthalpies of binding the first and second putrescine molecule, 
respectively.  ΔH1 and ΔH2 are both expressed per mol of monomer.  K1 and K2 are the 
apparent binding constants under the approximation that the free putrescine 
concentration is equal to the total concentration. 
The populations of each species in equilibrium were calculated as: 
 
)][][1(
1
][
][
2
211
2
LKKLKM
M
T
!!+!+
=  (5) 
)][][1(
][
][
][
2
211
12
LKKLK
LK
M
LM
T
!!+!+
!
=  (6) 
)][][1(
][
][
][
2
211
2
2122
LKKLK
LKK
M
LM
T
!!+!+
!!
=  (7) 
Fits to equations 3 and 4 were done using nonlinear fitting routine NLREG 
(http://www.nlreg.com/), as described previously (42). 
Putrescine Analysis. Putrescine was released from bound protein by treatment 
with perchloric acid and determined by reverse-phase HPLC using post-column 
derivatization with o-phthalaldehyde and fluorescence detection (43). 
Crystallization Conditions.  The protein was buffer exchanged into 10 mM N-
(2-hydroxyethyl)piperazine-N´-2-ethanesulfonic acid, pH 7.5, 200 mM NaCl and 1 
mM dithiothreitol (DTT) using Bio-Rad buffer exchange chromatography columns.  
For crystallization, the concentration of the protein was maintained at 10 mg/mL for 
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the E178Q(-Put) mutant and at 5 mg/mL for the D174N(-Put) and E256Q(-Put) 
mutant.  The crystals were grown using the hanging drop method at 22 °C in 13-16% 
polyethylene glycol 8000, 100 mM tris(hydroxymethyl)aminomethane, pH 7.5-8.5, 10 
mM DTT.  The crystals grew to a maximum size of 0.2 mm × 0.15 mm × 0.1 mm in 2-
3 days.  For the complexes of the mutants with MeAdoMet, each of the mutants was 
incubated with 4-6 molar excess of MeAdoMet for 24 h prior to crystallization.  To 
obtain structures of the mutants with putrescine bound, the E178Q and E256Q mutant 
proteins were incubated with 4-6 M excess of putrescine for 2 h prior to 
crystallization. 
Data Collection and Processing.  The data for the D174N(-Put), E178Q(-Put) 
and E256Q(-Put) were collected at the A1 station of the Cornell High Energy 
Synchrotron Source (CHESS) using a ADSC Quantum 210 detector.  Data for 
D174N(-Put) and E256Q(-Put) were collected over 180° with a 1° oscillation angle 
and 30 s exposure time per image at a crystal to detector distance of 175 mm.  Data for 
the E178Q(-Put) were collected over 110° with a 1° oscillation angle and 60 s 
exposure time per image at a crystal to detector distance of 185 mm.  The data for the 
putrescine free mutant complexes with MeAdoMet and E178Q(+Put) and 
E256Q(+Put) were collected at NE-CAT beamlines 24-ID-C and 24-ID-E, 
respectively, at the Advanced Photon Source (APS).  Data were collected over a range 
of 160° - 360° with a 1 s exposure time and a 1° oscillation range.  The crystal to 
detector distance varied between 200 – 280 mm. The data for the wild type 
AdoMetDC(-Put) were collected at a home source using a Rigaku R-AXIS IV++ 
detector and CuKα radiation from a Rigaku RU-300 rotating anode generator.  Data 
were collected over 140° with a 0.5º oscillation angle and 20 min exposure per 
oscillation with a crystal to detector distance of 180 mm.  The crystals were 
sequentially transferred to solutions with 2%, 5%, 8%, 15% and 18% glycerol with 1- 
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2 min equilibration between each step.  The crystals were flash frozen under liquid 
nitrogen for the MeAdoMet complexes and putrescine bound mutants and the crystals 
were directly flash frozen under a liquid nitrogen stream for putrescine free mutants 
and AdoMetDC(-Put).  The data were indexed, integrated and scaled using the 
HKL2000 program suite (44).  The data collection statistics are summarized in Table 
2.1 and 2.2 respectively. 
Structure Determination and Refinement.  All the structures were determined 
by molecular replacement using CNS (45).  The structure of 
AdoMetDC(+Put)/MeAdoMet (PDB ID 1I7B), minus pyruvoyl group, putrescine, 
MeAdoMet and water molecules, was used as the search model.  The model building 
for the E178Q(-Put) structure was done using the program O (46).  The model 
building for the rest of the structures was done using the program COOT (47).  The 
refinement process included successive rounds of simulated annealing, minimization, 
B-factor refinement, calculation of composite omit maps, difference Fourier maps and 
model building.  After a few rounds of refinement, the improved difference Fo-Fc 
Fourier map was used to identify ligands.  The ligand was then added to the model 
followed by another round of refinement and picking of water molecules.  The 
parameter and the topology files for MeAdoMet were generated using the HIC-Up 
server (48).  The difference Fo-Fc Fourier map was also used to identify conformational 
changes of residues in the putrescine binding site as well as the active site.  The final 
refinement statistics are given in Table 2.3 and 2.4 respectively.  A difference distance 
matrix program was used to identify conformational changes in the backbone of the 
protein structure (49, 50). 
Section 2.3. Results 
Studies were carried out with wild type AdoMetDC and three mutants of the 
protein in which acidic residues that hydrogen bond with putrescine (Figure 2.1 B)  
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Table 2.1. Data collection statistics for AdoMetDC mutants and complexes 
 
 D174N 
(-Put) 
E256Q 
(-Put) 
E178Q 
(-Put) 
D174N(-
Put) 
/MeAdoMet 
E256Q(-
Put) 
/MeAdoMet 
Wavelength (Å) 0.9764 0.9764 0.9766 0.9795 0.9795 
Space Group (Å) C2 C2 C2 C2 C2 
a (Å) 90.60 90.71 90.57 99.22 94.44 
b (Å) 55.24 55.90 56.26 50.60 50.08 
c (Å) 74.22 74.33 74.05 68.82 70.17 
β (°) 109.64 109.84 109.73 104.95 105.00 
Resolution (Å) 1.84 1.88 1.98 1.70 2.00 
Total reflections 88255 71106 53478 122776 54248 
Unique reflections 27642 27282 21433 35113 18180 
Redundancy 3.2(2.8) 2.6(2.3) 2.5(2.2) 3.5(2.5) 2.9(2.7) 
% completeness 92.1(73.8) 96.7(87.0) 89.8(89.4) 96.3(78.0) 84.0(72.6) 
I/σ 15.9(2.2) 16.0(2.0) 14.4(2.0) 15.4(2.2) 9.9(3.3) 
Rsym* 6.4(39.0) 4.9(39.6) 7.1(43.8) 8.3(32.8) 10.7(25.6) 
Matthews coef. 
(Å3/Da) 
2.28 2.31 2.32 2.18 2.09 
Solvent content (%) 45.1 45.9 45.9 42.5 40.1 
 
Values in parenthesis are for the highest resolution shell. 
* Rsym=ΣΣi|Ii - <I>|/Σ<I>, where <I> is the mean intensity of the N reflections with 
intensities Ii  and common indices h,k,l. 
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Table 2.2. Data collection statistics for AdoMetDC mutants and complexes. 
 
 E178Q(-Put) 
/MeAdoMet 
AdoMetDC 
(-Put) 
E178Q 
(+Put) 
E256Q 
(+Put) 
Wavelength (Å) 0.9795 1.5418 0.9792 0.9792 
Space Group (Å) C2 C2 C2 C2 
a (Å) 100.15 90.57 91.60 92.35 
b (Å) 51.07 55.54 54.49 53.54 
c (Å) 68.95 74.31 74.58 74.71 
β (°) 105.40 109.66 109.45 109.09 
Resolution (Å) 1.97 2.35 2.10 1.75 
Total reflections 73956 41261 69216 123289 
Unique reflections 23589 14524 19713 34072 
Redundancy 3.1(2.5) 2.8(2.6) 3.5(2.8) 3.6(3.0) 
% completeness 98.6(91.1) 99.1(95.7) 96.8(79.8) 97.7(89.6) 
I/σ 15.0(3.4) 13.9(2.0) 34.4(6.2) 30.1(4.6) 
Rsym* 8.0(23.8) 9.1(46.8) 3.7(12.2) 4.2(15.8) 
Matthews coef. 
(Å3/Da) 
2.22 2.30 2.29 2.28 
Solvent content (%) 43.5 45.5 45.3 45.0 
 
Values in parenthesis are for the highest resolution shell. 
* Rsym=ΣΣi|Ii - <I>|/Σ<I>, where <I> is the mean intensity of the N reflections with 
intensities Ii  and common indices h,k,l 
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Table 2.3. Refinement statistics for AdoMetDC mutants and complexes. 
 
 D174N 
(-Put) 
E256Q 
(-Put) 
E178Q 
(-Put) 
D174N(-Put)/ 
MeAdoMet 
E256Q(-Put)/ 
MeAdoMet 
Resolution (Å) 1.84 1.88 1.98 1.70 2.00 
R-factora 0.241 0.226 0.208 0.214 0.217 
R-freeb 0.278 0.254 0.243 0.239 0.245 
No of non-H atoms      
Protein 2424 2428 2433 2468 2470 
Ligand 8 8 12 28 28 
Water 182 153 109 176 201 
B-factors      
Protein (Å2) 48.5 47.8 38.6 32.7 35.9 
Ligand (Å2) 83.6 67.3 56.6 30.1 38.1 
rms deviations      
bonds (Å) 0.007 0.010 0.006 0.013 0.024 
angles 1.4 1.4 1.3 1.6 1.8 
dihedrals 25.8 25.7 25.4 27.7 28.6 
Ramachandran plot      
Most favored region (%) 89.6 90.1 91.2 90.5 90.0 
Additional favored region 
(%) 
8.8 9.5 7.3 7.6 9.6 
Generously allowed 
 region (%) 
0.4 0.4 0.4 1.5 0.0 
Disallowed region (%) 1.2 0.0 0.0 0.4 0.4 
 
aR-factor = Σhkl||Fobs|-k|Fcal||/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated 
structure factors, respectively.  In bR-free the sum is extended over a subset of 
reflections (5%) that were excluded from all stages of refinement 
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Table 2.4. Refinement statistics for AdoMetDC mutants and complexes. 
 
 E178Q(-Put)/ 
MeAdoMet 
AdoMetDC(
-Put) 
E178Q 
(+Put) 
E256Q 
(+Put) 
Resolution (Å) 1.97 2.35 2.10 1.75 
R-factora 0.205 0.222 0.219 0.230 
R-freeb 0.228 0.283 0.249 0.241 
No of non-H atoms     
Protein 2484 2456 2503 2500 
Ligand 28 8 14 6 
Water 222 110 142 220 
B-factors     
Protein (Å2) 29.6 52.3 40.5 31.9 
Ligand (Å2) 40.4 87.2 58.9 28.6 
rms deviations     
bonds (Å) 0.014 0.006 0.023 0.040 
angles 1.6 1.3 1.6 2.1 
dihedrals 27.4 24.3 25.6 26.2 
Ramachandran plot     
Most favored region (%) 90.9 86.2 90.8 91.2 
Additional favored region 
(%) 
8.0 12.3 8.5 8.8 
Generously allowed region 
(%) 
1.1 1.5 0.7 0.0 
Disallowed region (%) 0.0 0.0 0.0 0.0 
 
aR-factor = Σhkl||Fobs|-k|Fcal||/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated 
structure factors, respectively.  In bR-free the sum is extended over a subset of 
reflections (5%) that were excluded from all stages of refinement 
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were altered to the corresponding amides.  The proteins were dialyzed extensively to 
remove bound putrescine.  Direct analysis of the protein preparations confirmed that 
they contained <0.001mol putrescine/mol protein. 
Far-UV and Near-UV CD.  Far-UV CD spectroscopy was used to assess the 
effect of substitutions and putrescine binding on the secondary structure of the protein.  
Figure 2.2 A shows the Far-UV CD spectra for the wild type AdoMetDC and mutants.  
In all cases the spectra show a minimum at 218 nm and a maximum at 195 nm, typical 
of proteins with significant β-sheet content.  The difference in ellipticity among the 
proteins is within the experimental error indicating that these single amino acid 
substitutions did not perturb the secondary structure of AdoMetDC.  Figure 2.2 A 
inset shows the effect of putrescine binding on the wild type AdoMetDC secondary 
structure.  It can be seen that the holo protein has overall the same secondary structure 
as the apo form. The small difference observed might be due to contributions of the 
aromatic residues which interact with putrescine (Phe111, Phe285, Tyr318, Phe315 
and Phe320) (23, 30, 31). 
Near-UV CD is very sensitive to the environment of aromatic side chains and 
therefore to the tertiary structure of the protein.  Figure 2.2 B shows the near-UV CD 
spectra for the AdoMetDC wild type and variant proteins.  The overall shapes of the 
spectra are similar with a minimum at 278 nm and a maximum at 256 nm.  The small 
difference in absolute values observed among proteins is probably due to slightly 
different orientation of the aromatic residues caused by the substitutions.  Putrescine 
has a small effect on the near-UV CD for the wild type and E256Q proteins (Figures 
2.2 C and D, respectively).  Under saturated conditions of putrescine, the ligand causes 
a small increase in ellipticity, probably due to a more rigid environment of the 
aromatic residues.  On the other hand, no change in ellipticity was observed for 
E178Q and D174N, respectively (Figures 2.2 E and F, respectively). 
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Figure 2.2. (A) Effect of mutations on the Far-UV CD spectra for human wild 
type AdoMetDC (thick solid line), E256Q (thin solid line), D174N (dashed 
line) and E178Q (dashed-and-dotted line). Inset: Effect of putrescine on the 
Far-UV CD spectra: wild type protein in the absence (thick solid line) and 
presence (thin solid line) of putrescine. (B) Effect of mutations on the Near-
UV CD spectra for wild type AdoMetDC (thick solid line), E256Q (thin solid 
line), D174N (dashed line) and E178Q (dashed-and-dotted line). Effect of 
putrescine on the Near-UV CD spectra: wild type AdoMetDC (C), E256Q (D), 
E178Q (E) and D174N (F) in the absence (thick solid line) and presence (thin 
solid line) of putrescine. 
 
This is expected for D174N as the substitution abolishes putrescine binding to 
the protein (see later Results). 
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         Analytical Ultracentrifugation of the AdoMetDC Proteins.  The X-ray structure 
of the human wild type AdoMetDC shows that the protein crystallizes as a dimer (18, 
23). To assess if this is the functional unit in solution and if the putrescine or 
mutations affect the oligomerization state of the protein, sedimentation equilibrium 
experiments were performed at three different speeds.  For each protein the data were 
globally fitted according to different oligomeric models.  In all cases, the experimental 
data were best fitted according to a model with single species in equilibrium (equation 
2 in Materials and Methods) and a molecular weight of a dimer.  Figure 2.3 shows 
representative data for the wild type AdoMetDC.  The molecular weight obtained from 
the global fit was 77.2 +/-0.3 kDa in very good agreement with the theoretical one 
(76.8 kDa).   
Putrescine Binding to AdoMetDC Characterized by ITC.  In the ITC 
experiments, the heat released upon putrescine binding to the proteins was measured.  
Figure 2.4 A shows representative heat effects for putrescine binding to wild type 
AdoMetDC at 15 °C.  The heat of binding is proportional to the enthalpy and degree 
of binding and thus allows model-dependent estimates of the enthalpy (ΔH), the 
binding constant (K) and the stoichiometry (n).  Figure 2.4 B shows the binding 
isotherm in which the heat effect is plotted as a function of putrescine concentration.  
The experimental data were fitted according to equation 3 (in Materials and Methods), 
which considers independent and non interactive binding sites (scheme 1).  The n 
parameter was kept constant as 1 molecule of putrescine per monomer of wild type 
AdoMetDC.  It can be seen that the fit to model 1 does not represent the experimental 
data.  The binding isotherm was then fitted according to equation 4 (in Materials and 
Methods), which considers two interactive ligand binding sites per dimeric protein, 
according to the model shown in scheme 2.  The fitted parameters are summarized in 
Table 2.5.  We observed that the second putrescine molecule binds with significantly  
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Figure 2.3. Equilibrium sedimentation analysis of human AdoMetDC. Representative 
traces for the wild type AdoMetDC at 12,000 (circles), 15,000 (squares) and 20,000 
rpm (triangles). Solid lines represent the global fit according to equation 2. The 
molecular weight obtained from the fit was (77.2 ±0.1) kDa. 
 
higher affinity to the dimeric protein than the first one.  We found that K2 > K1/4 
which implies that putrescine binding to the wild type AdoMetDC protein has positive 
cooperativity.  The cooperativity in a two-site system can be characterized by  
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We observe that ΔΔG is very significant (Table 2.5) if we compare it to the ΔG for the 
total process from the apo to the holo forms.  The ΔG for this process is calculated as 
 
( )
21
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Figure 2.4 C shows the changes in the population of the different species in 
equilibrium as a function of the putrescine concentration according to equations 5, 6 
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Figure 2.4. Putrescine binding to wild type AdoMetDC by ITC. (A) Representative 
isothermal titration calorimetry experiment at 15 °C. Heat effects are recorded as a 
function of time during 45 successive 3 µL injections of 0.70 mM solution of 
putrescine into the cell containing 0.0138 mM protein (a) or buffer (b). Buffer 
conditions were 50 mM sodium phosphate pH 7.5, 1 mM EDTA, 1 mM TCEP. (B) 
Cumulative heat effect corresponding to the titration in panel A (o) as a function of 
putrescine concentration. The thin line is the fit of the experimental data to equation 
3. The thick line is the fit of the experimental data to equation 4 with the parameters 
listed in Table 3. (C) Populations present in solution as a function of putrescine 
concentration: [M2]/[MT] (thick solid line), [M2L]/[MT] (dashed line) and 
[M2L2]/[MT] (thin solid line) calculated according to equations 5, 6 and 7, 
respectively. 
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Table 2.5.  Thermodynamic parameters for putrescine binding to the AdoMetDC 
proteins from the ITC experiments at 15 °Ca.   
 
Protein K1  K2  ΔH1 ΔH2 ΔG ΔΔGcoop 
AdoMetDC(-Put) 9x104 3.4x105 -5.8 1.2 -13.8b -1.55c 
E256Q(-Put) 1.0x104 - -6.1 - -10.3b NA 
E178Q(-Put) 2.0x103 - -1.2 - -8.7b NA 
D174N(-Put) NE - NE - NE NA 
 
a The binding constants are expressed in M-1, the enthalpies are expressed in kcal 
per mol of monomer and free energies are expressed in kcal/mol.  The error in the 
enthalpies and binding constants is ~15%.  Note that for E256Q and E178Q, 
K1=K2=K and ΔH1=ΔH2; NA: not applicable; NE - no heat effect was observed for 
D174N. b calculated according to equation (9); c calculated according to equation (8)  
 
and 7 in Materials and Methods.  We observe that the M2L concentration is never 
higher than 20% of the total protein and the high cooperativity favors the binding of 
the second putrescine molecule (M2L2).  The stoichiometry of the interaction is 
consistent with the crystal structure of the human AdoMetDC protein which shows 
that each monomer is able to bind one molecule of putrescine (23, 30, 31). 
Figure 2.5 shows the putrescine binding isotherms for the AdoMetDC mutant proteins 
at 15 °C.  One obvious conclusion can be drawn from these results: the putrescine 
binding to the D174N variant does not show any significant heat effect (Figure 2.5 C), 
strongly suggesting that AdoMetDC-D174N is no longer able to bind putrescine.  To 
ensure that the lack of heat effect was due to lack of binding and not to a very small 
enthalpy of binding at that temperature or not enough protein concentration, 
experiments were performed at different temperature and different protein 
concentrations (results not shown).  In all cases, titration of the D174N variant protein 
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with putrescine produced no significant heat effect under our experimental conditions.  
Thus, substitution of Asp174 by asparagine abolishes putrescine binding all together. 
However, the putrescine binding to the E256Q and E178Q variant proteins 
shows significant heat effects different from that with wild type AdoMetDC.  The 
isotherms for the E256Q and E178Q can be fitted according to equation 3 (model 1, 
Figures 2.5 A and 2.5 B).  The fitted parameters are summarized in Table 2.5.  It is 
obvious from these results that the mechanisms of putrescine interaction with the 
human AdoMetDC wild type protein and the E256Q, E178Q and D174N mutant 
proteins are very different.  Substitution of Glu178 or Glu256 by glutamine not only 
abolishes the positive cooperativity for the binding of the second molecule of 
putrescine to these proteins, but also dramatically decreases the putrescine binding 
affinity as compared to K1 for the wild type protein (Table 2.5).  
Crystal Structures of Putrescine Free AdoMetDC.  Crystal structures of 
AdoMetDC(-Put), D174N(-Put), E178Q(-Put) and E256Q(-Put) were obtained. 
Difference Fourier maps (Fo-Fc) and composite omit maps clearly show that putrescine 
was absent in these structures.  Instead the putrescine binding site in the AdoMetDC(-
Put) and D174N(-Put) and E256Q(-Put) mutants contains four additional water 
molecules (Figure 2.6 A).  The nitrogen atom of putrescine closer to the active site is 
replaced with a water molecule (WA).  This water molecule makes hydrogen bonds to 
water molecules WB and WC, which in turn are hydrogen bonded to Glu256 and 
Ser113, respectively.  A fourth water molecule (WD) is present roughly at the center of 
the putrescine binding site and hydrogen bonds to WA.  Asp174 is found in various 
conformations in the putrescine free structures and is not hydrogen bonded to any 
conserved water molecule.  The structure of the E178Q(-Put) mutant shows a ligand 
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Figure 2.5. Dependence of the heat effect of putrescine binding to AdoMetDC-E256Q 
(A), AdoMetDC-E178Q (B) and AdoMetDC-D174N (C) as a function of the ratio 
putrescine/protein. Solid lines are the best fit to equation 3 with the parameters in 
Table 2.5. 
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Figure 2.6. Putrescine binding site in the putrescine free mutants. (A) Stereoview of 
putrescine binding site in the E256Q(-Put) mutant. Water molecules are shown as red 
spheres and hydrogen bonds are shown as dashed lines.  (B) Stereoview of the 
putrescine binding site in the E178Q(-Put) mutant. The density maps show a planar 
ligand comprised of four atoms bound in the putrescine binding site. A molecule of 
urea was modeled into the density.  The difference Fo-Fc Fourier map is calculated 
omitting urea and is contoured at 4.0 σ.  The hydrogen bonds are omitted for clarity. 
 
bound in the putrescine binding site.  Based on the electron density, which is 
triangular and flat, a molecule of urea was modeled into the putrescine binding site.  
The carbonyl oxygen of urea occupies the same position as the putrescine amino group 
closer to the active site and WA, and is hydrogen bonded to the enzyme through water 
molecules.  A stereoview of the ligand bound in the putrescine binding site of the 
E178Q(-Put) mutant is shown in Figure 2.6 B. 
Three regions of the AdoMetDC show differences in the putrescine free 
structures relative to the putrescine bound structures: residues 171-173, 301-304 and 
  37 
315-320 (Figure 2.7).  In addition the side chains of Phe285, Ser 312 and Met314 
show different conformation in the putrescine free structures.  Loop 171-173 is 
adjacent to Asp174, which is required for putrescine binding.  Four aromatic residues, 
Phe285, Phe315, Tyr318 and Phe320, are repositioned in the putrescine free structures 
mostly through changes in the χ1 torsion angles plus lateral shifts (Figure 2.8).  The 
repositioning is associated with a 1.5 to 3 Å shift in loop 312-318 and causes the 
putrescine binding site to become more solvent exposed.  The biochemical relevance 
of loop 301-304 is unclear because it is far away from both the putrescine binding site 
and the active site. 
 
Figure 2.7. Dimeric form of AdoMetDC.  Putrescine and MeAdoMet bound in the 
active site are shown as sticks. There is no overall change in the secondary structure. 
The loops undergoing conformational upon putrescine binding are colored red and 
labeled.  
 
Crystal Structures of the Putrescine Free AdoMetDC/MeAdoMet Complexes.  
Complexes of putrescine free mutants with MeAdoMet were prepared to determine the 
effects of the absence of putrescine on the conformation of the substrate and active site 
residues.  Difference Fourier maps showed MeAdoMet bound in the active site of all 
three mutants covalently linked to the pyruvoyl cofactor through a Schiff base.  The  
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Figure 2.8. Stereoview of the changes in the conformation of aromatic side chains 
occurring due to putrescine binding. AdoMetDC(+Put) is shown in blue and 
AdoMetDC(-Put) is shown in gray. The conformational shift in loop Phe320-Ser312 
as an effect of the changes in the aromatic side chains is clearly seen. 
 
MeAdoMet conformation and the active site are essentially the same as for the 
complex of wt-AdoMetDC with MeAdoMet (30).  The 2´ and 3´ oxygen atoms of the 
ribose each make a hydrogen bond to the carboxylate group of Glu247.  The adenine 
base stacks between Phe7 and Phe223 with an overall syn conformation.  All three 
mutant complexes, including E178Q, showed the same four conserved water 
molecules in the putrescine binding site.  The mutant complexes also showed the same 
reorganization of the four aromatic residues Phe285, Phe315, Tyr318 and Phe320 and 
the conformational change in loop 312-320 seen without putrescine and substrate 
analog. 
Structure of Mutants with Added Putrescine.  Structures of E178Q and E256Q 
were determined after the addition of putrescine.  The structure of D174N with 
putrescine was not determined because biochemical studies reported here show that 
this mutant does not bind putrescine.  For both E178Q(+Put) and E256Q(+Put) 
addition of putrescine resulted in a reversal of the conformational changes in Phe285, 
Phe315, Tyr318 and Phe320 and the 312-320 loop seen in the putrescine free 
structures (Figure 2.8).  The putrescine molecule is in the same position as observed in 
all previously reported human AdoMetDC structures (23, 30, 31).  In both structures 
the aliphatic chain of putrescine stacks against Phe111 and Phe285, with the latter 
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residue involved in repositioning the aromatic residues for the putrescine free 
structures. 
In the E256Q(+Put) mutant, one end of putrescine makes direct hydrogen 
bonds to Glu15, Asp174 and Thr176 while the other end makes water mediated 
hydrogen bonds to Glu178 and Gln256 as previously observed (23, 30, 31).  The 
E178Q(+Put) mutant structure shows some interesting differences.  One end of the 
putrescine molecule makes direct hydrogen bonds to Glu15, Asp174 and Thr176 and 
the other end of the putrescine makes a water mediated hydrogen bond with Glu256; 
however, there is no bridging water molecule between putrescine and Gln178.  
Additionally, compared to all other AdoMetDC structures, there is a conformational 
change in residues Glu11, Lys80, Ser229 and His243 in E256Q(+Put), which link the 
putrescine binding site and the active site (Figure 2.9).  The χ1 torsion angle of 
His243, which is important for both the processing and decarboxylation reactions, 
changes from -63° to 90°.  In the alternate conformation the side chain is pointed away 
from both the pyruvyl cofactor and Ser229.  Residues Lys80 and Glu11 also undergo 
conformational changes and are hydrogen bonded to each other through Ser254 and a 
water molecule.  The other significant change in E256Q(+Put) is the transformation of 
the disordered loop 291-299 into a short α-helix. This helix is located at the dimer 
interface and interacts across the twofold axis with the same helix from the other 
protomer.  The closest contact between the two helices is at the sulfur atoms of 
Cys292, which are 3.6 Å apart. 
Section 2.4. Discussion 
Putrescine Binding to AdoMetDC and Mutants.  Activation of the AdoMetDC 
autoprocessing and decarboxylation reactions is species dependent.  The regulation of 
the polyamine biosynthetic pathway by putrescine in certain species is poorly 
understood and a thorough understanding of the regulation of polyamine levels might  
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Figure 2.9. Stereoview of the comparison of the catalytic residues His243, Glu11, 
Lys80 and Ser229 in E256Q(+Put) and E256Q(-Put) mutants. E256Q(+Put) has 
carbon atoms colored in green and E256Q(-Put) has carbon atoms colored yellow. 
 
provide an alternate route for inhibiting the pathway.  However, the activation of 
autoprocessing and decarboxylation processes of human AdoMetDC by putrescine and 
other diamines is well known and studied (23).  The rate of activation of the enzyme is 
highest by putrescine when compared to other diamines.  The only previous direct 
measurements of putrescine binding to AdoMetDC were carried out with the T. cruzi 
enzyme (29).  The Kd, which was determined by ultrafiltration and by fluorescence 
change measurements, was 150-180 µM.  This is more than an order of magnitude 
greater than the values measured here by ITC for the human enzyme but, as described 
below, it has been shown recently that a much more active enzyme that is not 
putrescine-activated is formed by a heterodimer between T. cruzi AdoMetDC and a 
structurally homologous regulatory protein (51).  Although Asp174 appears to be a 
key residue in binding for both enzymes since mutation to valine in T. cruzi (29) or 
asparagine in human (Table 2.5) abolished binding, it appears that there is little 
similarity in the activation of the parasite and mammalian enzymes.  Our value is 
much closer to that which would be expected on the basis of the amount of putrescine 
needed for enzyme activation (Ka of c. 20 µM) (3, 19-21) or processing (Ka c. 50 µM) 
(23).  The latter value may be increased due to competition for binding by nucleic 
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acids in the reticulocyte lysates used for studying processing in coupled 
transcription/translation systems. 
The tight binding of putrescine to human AdoMetDC is also consistent with 
the difficulty in removing putrescine from the enzyme.  This requires extensive 
dialysis and it is noteworthy that all of the previously published structures of the 
protein contain a bound putrescine even though it was not added to the buffers used 
for crystallization.  The current results using ITC confirm that there is only one 
putrescine binding site in the human AdoMetDC αβ protomer and rules out postulated 
models in which two putrescine molecules bring about the changes in AdoMetDC 
activity (19, 34, 52).  The previously unrecognized cooperative binding of putrescine 
to mammalian AdoMetDC is likely to explain the complex kinetics for activation 
previously reported (52).  Furthermore, the ITC data confirm that in solution, the 
putrescine molecule binds in the site identified by the crystal structure.  Mutation of 
Asp174, which interacts directly with the putrescine, totally abolished binding, 
highlighting the effect of the hydrogen bond from this residue upon putrescine 
binding.  Mutations of Glu178 and Glu256, which both interact indirectly via a water 
molecule, greatly reduced the affinity for putrescine.  Potato AdoMetDC, which is not 
activated by putrescine, is generally quite similar to the human structure but is an αβ 
monomer (35).  In this structure, several amino acid substitutions in the putrescine 
binding pocket (Asp174 to valine, Phe111 to arginine, Leu13 to arginine and Phe285 
to histidine) introduce side chains that mimic the role of putrescine in the human 
enzyme.  Thus, dimerization and putrescine activation may be linked. 
Structure of the Putrescine Binding Site with and without Putrescine.  Previous 
structural studies clearly identified the putrescine binding site in human AdoMetDC 
(23, 30, 31).  Putrescine is bound between the two central β-sheets of the enzyme at a 
distance of 15 to 20 Å from the active site.  The putrescine amino group farther from 
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the active site is directly hydrogen bonded to Asp174, Glu15 and Thr176.  The closer 
amino group is hydrogen bonded through water molecules to Glu178, Glu15, Glu256 
and Ser113.  The carbon chain of putrescine stacks against Phe285 and Phe111.  The 
crystal structure also shows that there is only one molecule of putrescine bound per 
monomer.  
Previously reported structures provided insights into the mechanism of 
putrescine activation of human AdoMetDC (23).  On the basis of these studies, the 
mechanism of putrescine activation was believed to be due to two reasons.  First, 
putrescine binds inside the β-sandwich region through charge neutralization of acidic 
residues and hydrophobic interactions to aromatic residues and it was proposed that 
stability of the β-sandwich is necessary for the correct orientation of residues for the 
autoprocessing reaction.  Second, there is a hydrogen bonding network from the 
putrescine binding site to His243, which plays a critical role in the autoprocessing 
mechanism and in the decarboxylation processes through electrostatics and hydrogen 
bonding.  
The crystal structures of the putrescine free enzyme and mutants provide newer 
insights into the putrescine binding site.  The putrescine binding site is solvent 
accessible from one side and in the absence of putrescine the site is filled with water 
molecules.  The comparison of crystal structures of putrescine free and putrescine 
bound AdoMetDC structures showed no significant changes in the secondary 
structure.  The Far-UV CD experiments have also shown that there is no significant 
change in the secondary structure of AdoMetDC and the mutants upon putrescine 
binding, supporting the crystal structures. These observations suggest that putrescine 
has little effect in stabilizing the secondary structure of the enzyme as previously 
thought. 
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Conformational Changes upon Putrescine Binding.  Difference distance matrix 
analysis (49, 50) showed significant changes in the Cα positions of residues 171-173, 
301-304, 312-320.  Asp174 is required for putrescine binding and residues 171-173 
are near the entrance of the putrescine binding site.  Consequently, these residues 
appear to serve as a gate to the putrescine binding site.  In addition repositioning of the 
aromatic residues Phe285, Phe315, Tyr318 and Phe320 and the loop containing 
residues 312-320 further opens the putrescine binding site (Figure 2.8).  In the absence 
of putrescine, the site is filled with water, more open and more solvent accessible.  
Binding of putrescine displaces two water molecules and Phe285 moves towards the 
aliphatic portion of the putrescine molecule, followed by closing off of the entrance 
thus shielding the putrescine from the solvent.  These changes result in closer contacts 
between the protein side chains and an enhancement of electrostatic effects.  The near-
UV CD experiments showed a small effect for the wt-AdoMetDC and the E256Q 
mutant, which is due to the change in the aromatic side chain positions.  This finding 
is in agreement with the change in the orientation of Phe285, Phe315, Tyr318 and 
Phe320 observed upon putrescine binding. 
Positive Cooperativity of Putrescine Binding.  Human AdoMetDC is a 
homodimer with two active sites and two putrescine binding sites.  ITC studies 
showed positive cooperativity of putrescine binding for WT-AdoMetDC while no 
cooperativity was observed for the mutants (Table 2.6).  Loop 312-320, which 
undergoes a shift upon putrescine binding, is at the dimer interface (Figure 2.10 A).  
The main contacts between this loop and the twofold related protomer occur between 
the residues Ser312-Ser312´, Met314-Cys310´, Phe315-Arg307´ and Gln311-Gln311´, 
where the prime designates residues in the twofold related protomer.  The effect of 
putrescine binding and conformational changes in the loop provide a possible 
mechanism by which changes in one putrescine binding site are relayed through the 
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dimer interface to the putrescine binding site in the other monomer.  Not consistent 
with this argument is that the E178Q and E256Q mutants bind putrescine but do not 
show cooperativity even though the same conformational changes are observed upon 
putrescine binding for loop 312-320 and the four aromatic residues, suggesting that 
other factors are involved. 
Table 2.6. Effects of putrescine on AdoMetDC and mutants. 
 Processing 
(-Put) 
Processinga 
(+Put) 
Decarboxyl- 
ation (-Put) 
Decarboxyl- 
ationb 
(+Put) 
Cooperativity 
in Put 
binding 
WT 1 5-8 1 4 yes 
D174N 1 NA 1 NA NA 
E178Q 1 1 4 1 none 
E256Q 1 1 1 1 none 
a Activation measured at 1 mM Put (23) 
b Activation measured at 0.2 mM Put (32) 
Structural Insights into Putrescine Stimulation of AdoMetDC Activity.  
Structural comparisons suggest no global conformational changes upon putrescine 
binding to AdoMetDC; however, several local conformational changes are observed.  
This suggests that the primary effect of putrescine is electrostatic and that this effect is 
transmitted to the active site though hydrogen bonding (Figure 2.10 B).  Binding of 
putrescine introduces two positive charges into a binding pocket that contains three 
conserved acidic residues.  Glu178 and Glu256, are hydrogen bonded through water to 
the putrescine amino group closer to the active site and are near Lys80, which is 
disordered in most AdoMetDC structures.  Lys80 is also near Glu11 and His243, two 
residues important for both autoprocessing and catalysis.  Through this network the 
pKa of His243 would increase in the presence of putrescine and decrease in the 
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absence.  His243 is proposed as the base for proton abstraction needed for the 
cleavage of the ester intermediate (23, 33).  It may also play a role in the 
decarboxylation reaction but this cannot be assessed using mutants since the 
autoprocessing step is essential for activity.  The side chain of Glu11 is positioned to 
assist in protonation/deprotonation of the His243.  Glu11 is an essential residue for the 
activation by putrescine although it plays no direct role in putrescine binding.  
Mutation of Glu11 to glutamine abolishes putrescine activation of processing (34) and 
mutation to aspartate causes putrescine to be an inhibitor of processing (23).  Mutation 
E11K prevents processing completely (34).  Mutation E11Q greatly reduces 
AdoMetDC activity (34) and reduces the stimulation by putrescine by 60%.  The 
E11D change reduces activity of the processed enzyme by about 4-fold and putrescine 
activation by about 50% (unpublished).  The mutant K80A has only about 10% 
activity and is stimulated by putrescine only at very high concentrations with a Ka of 
400 µM.  Similarly, the processing of this mutant is much slower than wild type and is 
putrescine activated but requires much higher levels of putrescine  (Ka of c. 1 mM).  
Combination of the K80A/E11D mutation abolishes the inhibitory effect on 
processing of this mutation and the K80A and K80A/E11D mutants have identical 
responses to putrescine (unpublished).  ITC binding results show that the D174N 
mutant protein does not bind putrescine.  Asp174 hydrogen bonds to the putrescine 
amino group away from the active site and initiates the conformational changes that 
close the putrescine binding site and shield it from the solvent.  The E178Q and 
E256Q mutants bind putrescine but show no stimulation of processing.  Both 
glutamate/glutamine residues interact through water with putrescine and also 
participate in the hydrogen bonding network that links the putrescine binding site and 
active site.  The negative charge appears to be key for influencing active site 
electrostatics and its absence blocks the effects of putrescine. 
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Figure 2.10. (A) Dimer interface of AdoMetDC. The monomers are colored green and 
gray respectively. The loop 315-320 is colored red one monomer and blue in the other. 
The residues at the interface are shown in sticks.  (B) Charge network between the 
putrescine binding site and the active site. Putrescine, MeAdoMet and the active site 
pyruvoyl group carbon atoms are colored green. Water molecules are shown as red 
spheres and hydrogen bonds are shown as dashed lines. 
 
In contrast the E178Q mutant has decarboxylation activity in the absence of 
putrescine comparable to wild type with putrescine, while the decarboxylation activity 
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of the E256Q mutant is not simulated by putrescine.  These results are consistent with 
a proposed model of charge relay through Lys80 to Glu11 to His243 resulting from 
putrescine binding. 
Another possibility is that putrescine utilizes electrostatic interactions to 
correctly position active site residues.  Evidence for a structural switch comes from the 
structure of the E256Q(+Put), which shows conformational changes in Glu11, Lys80, 
Ser229 and His243.  The largest change occurs in His243, which rotates about its  χ1 
torsion angle by about 150 degrees.  In this conformation the side chain is pointed 
away from both the pyruvoyl cofactor and Ser229.  Previous biochemical data shows 
that the catalytic activity of the E256Q(-Put) mutant is far lower than the wild type 
enzyme and is not stimulated by the addition of putrescine (32), suggesting this 
positioning of residues represents a low activity state in which putrescine is unable to 
influence the correct positioning of active site residues.  The structure E178Q(+Put) 
lacks a bridging water molecule between putrescine and Gln178, resulting in no 
activation of the E178Q(-Put) mutant by putrescine. 
 Implications for Other AdoMetDCs:  The effect of putrescine varies among 
species.  Class 1a and 1b enzymes have a fold that is similar to both the N-terminal 
and C-terminal halves of the class 2 protomer; however, class 1 AdoMetDCs do not 
have a putrescine binding site and are not stimulated by putrescine.  Class 2a 
AdoMetDCs include the plant enzymes and have a fold very similar to the class 1a 
protomer but are monomeric rather than dimeric (35).  The class 2a enzymes contain a 
buried cluster of charged residues that is reminiscent of the putrescine binding site 
found in human AdoMetDC; however, the pocket is filled by two arginine residues 
that are not present in any class 2b enzyme.  Class 2a AdoMetDCs are not stimulated 
by putrescine but have constitutive processing and decarboxylation activities similar to 
those of the putrescine activated human AdoMetDC. 
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Multiple sequence alignments show that all of the key active residues are 
conserved in the class 2a and class 2b AdoMetDCs as are the residues that connect the 
buried charged cluster.  Class 2a and 2b are distinguished in part by the nature of the 
buried cluster.  Within class 2b there are two subclasses.  The first is represented by 
human AdoMetDC and is distinguished by a conserved Lys80.  Within this group the 
three acidic residues in the putrescine binding site are conserved.  The four aromatic 
residues are not entirely conserved; however, these residues are always aromatic or 
large hydrophobic residues.  The second subclass includes apicomplexan parasites and 
is distinguished by the substitution of isoleucine in place of Lys80.  A hydrophobic 
residue would interrupt the electrostatic transfer of charge and suggests that putrescine 
stimulates this group of AdoMetDCs by a different mechanism than that of human 
AdoMetDC.  Studies on the Trypanosome brucei AdoMetDC showed that putrescine 
stimulates the decarboxylation reaction; however, the activity was about 1000-fold 
lower than the activity of the human AdoMetDC (51).  Recently, Phillips and 
coworkers showed that formation of a heterodimer between AdoMetDC and a 
structurally homologous but inactive regulatory protein resulted in decarboxylation 
rates comparable to human AdoMetDC (51).  Furthermore, the heterodimeric T. 
brucei AdoMetDC was not stimulated by addition of putrescine.  No structures are 
available for this group of AdoMetDCs and the mechanism of stimulation remains to 
be determined. 
Regulating polyamine levels by controlling the enzymes in the polyamine 
biosynthetic pathway is a promising target for cancer and anti-parasitic therapy (6, 7). 
Our results suggest that an alternate approach to inhibiting AdoMetDC would be to 
target the putrescine binding site.  Compounds binding to this site that mimic the 
effects of some of the mutants described above may prevent processing or 
significantly block activity. 
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CHAPTER 3 
ROLE OF THE SULFONIUM CENTER IN DETERMINING LIGAND 
SPECIFICTY OF HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE2 
Section 3.1. Introduction 
The polyamines putrescine, spermidine and spermine are aliphatic polycations 
that are critical for maintaining cell differentiation and proliferation (1-3).  Elevated 
levels of polyamines are found in cancerous and tumor cell lines (4, 5).  Thus, 
depleting polyamine levels by inhibition of the polyamine biosynthetic pathway is a 
promising approach for the treatment and prevention of cancer and also for the 
treatment of various parasitic diseases.  S-adenosylmethionine decarboxylase 
(AdoMetDC) is a key enzyme in the polyamine biosynthetic pathway and depends on 
a pyruvoyl cofactor for the decarboxylation reaction (6-9).  AdoMetDC catalyzes the 
decarboxylation of S-adenosylmethionine (AdoMet) to S-adenosyl-5´-(3-
methylthiopropylamine) (dcAdoMet).  The aminopropyl group from dcAdoMet is 
transferred to putrescine or spermidine to form spermidine or spermine, respectively.  
AdoMetDC catalyzes an early step in the pathway and dcAdoMet is completely 
committed to polyamine biosynthesis; thus, AdoMetDC is an attractive target for drug 
design. 
The early inhibitors of AdoMetDC included the potent competitive inhibitor 
methylglyoxal bisguanylhydrazone (MGBG) (10).  Clinical studies on this compound 
were hampered by an unexpected mitochondrial toxicity unrelated to its inhibition of 
AdoMetDC.  An MGBG analogue, 4-amidinoindan-1-one-2´-amidinohydrazone 
(CGP48664A) showed promise in multiple phase I and phase II clinical trials (11-18).  
Irreversible (or slowly reversible) substrate analogue inhibitors, which form a Schiff 
                                                
2 Reproduced with permission from Biochemistry, submitted for publication. Unpublished work 
copyright 2009 American Chemical Society. 
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base with the active site pyruvoyl group, have also been synthesized but are limited by 
their nonspecific activity towards cellular aldehydes and ketones (19).  In vitro assays 
showed that a positive charge at the position of the sulfonium ion is essential for 
ligand binding and inhibition (20).  Thioether and sulfoxide substrate analogues, 
which lack the positive charge, showed no activity.  Alternately, replacement of a 
sulfur atom with a nitrogen atom, which is protonated at physiological pH and retains 
the positive charge, resulted in AdoMetDC inhibition.  This is consistent with the 
observation that S-adenosylhomocysteine (SAH) is not a substrate for AdoMetDC 
(21). 
Previously, the structure of AdoMetDC and its complexes with inhibitors 5´-
deoxy-5´-[N-methyl-N-(3-hydrazinopropyl)amino]adenosine (MHZPA), 5´-deoxy-5´-
[N-methyl-N-[(2-aminooxy)ethyl]amino]adenosine (MAOEA), the methyl ester of 
AdoMet (MeAdoMet), MGBG and CGP48664A were determined (22).  MGBG and 
CGP48664A act as competitive inhibitors of the enzyme and stack between Phe7 and 
Phe223, and form hydrogen bonds with Glu247, Ser229 and the backbone amide of 
Leu65.  The substrate analogues MHZPA, MAOEA and MeAdoMet have positive 
charges at the sulfonium ion position and covalently bind to the enzyme acting as 
slowly reversible inhibitors.  The adenine base of these inhibitors stacks between Phe7 
and Phe223, the glycosidic bond adopts an unusual syn conformation, and both ribose 
hydroxyl groups hydrogen bond to Glu247.  The requirement for a positive charge in 
substrate analogues remained puzzling because no negatively charged amino acid side 
chain was located nearby. 
We chose to investigate the basis of the ligand specificity of AdoMetDC using 
crystallography, quantum chemical calculations and stopped-flow kinetic experiments.  
We determined crystal structures of the enzyme co-crystallized with 5´-deoxy-5´-
(dimethylsulfonio)adenosine (MMTA) and 5´-deoxy-5´-(N-dimethyl)amino-8-
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methyladenosine (DMAMA).  The energy difference between the syn and anti 
conformation of the ligands in solution and in the active site of the enzyme was 
obtained using quantum chemical calculations.  Stopped-flow kinetic experiments 
were carried out to investigate the importance of Phe7 and Phe223, two residues 
located near the positive charge.  Our results show that ligand specificity in human 
AdoMetDC is mainly due to cation-π interactions and to electrostatic interactions 
between N3 of adenine and the sulfonium ion, which stabilizes the syn conformation. 
Section 3.2. Materials and Methods 
Materials.  The syntheses of MMTA and DMAMA were previously reported 
(23) and the compounds were the gift of Dr. Jack Secrist at Southern Research 
Institute. 
Protein Expression and Purification.  The plasmid encoding the enzyme was 
cloned into a pQE30 vector and transformed into JM109 strain E. coli cells.  An 
overnight culture of 10 mL was grown in LB media at 37 °C with 100 mg/mL 
ampicillin for resistance and then introduced into larger cell cultures of 1 L volume 
containing 100 mg/mL ampicillin.  The cells were grown until they reached an O.D600 
of 0.6 and then induced with 100 mg/L isopropyl-1-β-D galactopyranoside.  The 
temperature was reduced to 15 °C and the cells were allowed to grow and express the 
protein overnight.  The cells were harvested by centrifugation and washed using a 
wash buffer containing 20 mM Na2HPO4, pH 7.0, 500 mM NaCl, 2.5 mM putrescine, 
0.02% polyoxyethyleneglycol dodecyl ether (Brij-35) and 10 mM imidazole and 
stored at -80 °C.  The frozen cell pellet was resuspended in the wash buffer and lysed 
using a French press at 1500 psi.  The cellular debris was separated from the lysate by 
centrifugation at 12000 g.  Talon metal affinity resin was equilibrated with the wash 
buffer and the protein was bound to the resin by gently spinning the lysate and the 
resin together for 1.5 h.  The resin was loaded onto a column and washed with the 
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wash buffer 15-20 times the column volume.  The washing was continued with the 
wash buffer containing 25 mM imidazole.  The protein was eluted with the wash 
buffer containing 100 - 200 mM imidazole.  The elute was concentrated to around 10 
mL and passed through a Sephadex G-75 column pre-equilibrated with 10 mM N-(2-
hydroxyethyl)piperazine-N´-2-ethanesulfonic acid (HEPES), pH 7.5, 2.5 mM 
putrescine, 5 mM DTT, 0.1 mM ethylene diamine tetraacetic acid (EDTA), 0.02 % 
Brij-35 and 300 mM NaCl.  The fractions containing the protein were identified by 
UV peaks at 280 nm and collected.  The protein was concentrated to 10 mg/mL and 
stored at -80 °C. 
Crystallization.  The protein was buffer exchanged into 10 mM HEPES, pH 
7.5, 200 mM NaCl and 1 mM DTT using Bio-Rad buffer exchange chromatography 
columns.  The protein was incubated separately with a 4-6 molar excess of MMTA 
and DMAMA for 24 h prior to crystallization.  The crystals were grown using the 
hanging drop method at 22 °C in 13-16% polyethylene glycol 8000, 100 mM 
tris(hydroxymethyl)aminomethane, pH 8.0-9.0 and 10 mM DTT.  Crystals appeared 
overnight and were stable for 1-2 weeks but deteriorated after that. 
Data Collection and Processing.  The crystals were sequentially transferred to 
solutions containing the well solution with 2%, 5%, 8%, 15% and 18% glycerol with 
1-2 min equilibration between each step.  The crystals were flash frozen under liquid 
nitrogen before being placed in the liquid nitrogen stream.  The data for the complex 
of AdoMetDC with MMTA were collected at NE-CAT beamline 8-BM at the 
Advanced Photon Source using a ADSC Quantum 315 detector (Area Detector 
Systems Corporation).  Data were collected over a rotation range of 200º with an 
oscillation range of 1º and 60 s exposure per frame with a detector to crystal distance 
of 320 mm.  The data for the complex of DMAMA were collected at the NE-CAT 
beamline 24-ID-C.  Data were collected over a rotation range of 200º with an 
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oscillation range of 1º and 1 s exposure per frame with a detector to crystal distance of 
250 mm.  The data for the complexes were indexed, integrated and scaled using the 
HKL2000 program suite (24).  The data collection statistics for both complexes are 
summarized in Table 3.1. 
Structure Determination and Refinement.  The structures of the complexes 
were determined by molecular replacement with CNS (25) using the structure of the 
AdoMetDC/MeAdoMet complex (PDB code 1I7B) as the search model.  Model 
building for the complex of MMTA was performed using the program O (26).  The 
model building for the complex of DMAMA was performed using the program Coot 
(27).  The initial model obtained from molecular replacement was adjusted using 
composite omit maps and refined using successive rounds of simulated annealing, 
minimization, B-factor refinement, generation of new composite omit maps, 
difference Fourier maps and model building.  After a few rounds of refinement, the 
positions and the conformations of the ligand molecules were identified using the 
improved difference Fourier maps and composite omit maps.  The ligands were 
included in the models and water molecules were added based on the peaks in the 
difference Fourier maps.  The parameter and the topology files for the ligands were 
generated using the HIC-Up server (28).  The difference maps also showed density for 
a molecule of putrescine bound in each of the structures.  The final refinement 
statistics for both complexes are given in Table 3.2. 
Quantum Mechanical Calculations.  The quantum chemical calculations on the 
cation-π interactions were performed using Jaguar version 6.0 or 6.5 (Schrödinger).  
The X-ray structure of MMTA bound to AdoMetDC was employed for these 
calculations and single point energy calculations were performed using the LMP2/6-
31G** method on the following: (CH3)3S+ (from MMTA) plus two benzene rings 
(from Phe7 and Phe223); (CH3)3S+ (from MMTA) plus one benzene ring (from 
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Phe223); (CH3)3S+ (from MMTA) plus one benzene ring (from Phe7); (CH3)3S+ alone; 
benzene alone; (CH3)2S (from MMTA) plus two benzene rings (from Phe223 and 
 
Table 3.1. Data Collection Statistics for AdoMetDC Complexes 
 
 AdoMetDC + MMTA AdoMetDC + DMAMA 
Wavelength (Å) 0.9795 0.9795 
Space Group (Å) C2 C2 
a (Å) 93.85 99.45 
b (Å) 49.54 50.02 
c (Å) 70.00 68.69 
β 105.03 105.32 
Resolution (Å) 2.24 1.81 
Total/Unique reflections 56742/15123 107489/29093 
Redundancya 3.9(4.0) 3.7(2.5) 
% complete 95.1(99.4) 95.8(73.5) 
I/σ 8.9(4.26) 17.7(3.4) 
Rsymb 10.5(31.7) 7.9(21.5) 
Matthews no. 2.05 2.19 
Solvent content 38.9 42.9 
 
aValues for the highest resolution shell are given in parentheses. 
bRsym = ΣΣiIi - <I> | /Σ<I>, where <I> is the mean intensity of the N reflections with 
intensities Ii  and common indices h,k,l. 
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Table 3.2.  Refinement Statistics for AdoMetDC Complexes 
 
 AdoMetDC+MMTA AdoMetDC+DMAMA 
Resolution (Å) 2.24 1.81 
R factora 0.226 0.193 
Rfreeb 0.274 0.218 
No of non-H atoms   
Protein 2405 2439 
Ligand 21 22 
Water 76 234 
B-factors   
Protein (Å2) 32.6 29.3 
Ligand (Å2) 43.1 22.8 
Putrescine (Å2) 35.0 47.7 
rms deviations   
bonds (Å) 0.006 0.008 
angles (°) 1.3 1.3 
dihedrals (°) 25.1 25.3 
Ramachandran plot   
Most favored region (%) 90.7 92.0 
Additional favored 
region (%) 
8.5 6.9 
Generously allowed 
region (%) 
0.8 0.8 
Disallowed region (%) 0.0 0.4 
 
aR factor = Σhkl||Fobs|-k|Fcal|/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated 
structure factors respectively.  
bFor Rfree, the sum is extended over a subset of reflections (5%) excluded from all 
stages of refinement. 
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 Phe7); (CH3)2S alone.  The level of theory for the calculations is sufficient to account 
for the polarization effect and hence cation-π interactions (29). 
The energies and conformations of MMTA and 5´-deoxy-5´-methyl 
thioadenosine (MTA) in solution were determined starting with the NMR structure of 
AdoMet in solution (30) and truncating the molecule to MMTA or MTA.  The syn 
conformation was obtained by adjusting the O-C1´-N9-C4 torsion angle.  The 
structures were subjected to geometry optimization using the B3LYP/6-31G* density 
functional method and the SCRF implicit aqueous solvation model available in Jaguar.  
The single point energy of the geometry optimized structures was then obtained using 
the Local Moller-Plesset second-order perturbation (LMP2)/cc-PVTZ(-f) method with 
aqueous self-consistent reaction field (SCRF) solvation. 
The energies of the syn and anti conformations of MMTA in complex with the 
enzyme were determined using the MMTA complex as the basis.  The truncated 
model for the syn conformation consisted of MMTA and residues Phe223 and Phe7.  
Backbone atoms of the adjacent residues were also included in the calculations.  In 
addition, an acetate moiety derived from Glu247 was included.  Hydrogen atoms were 
added to the model.  Constrained geometry optimization was performed at the Hartree- 
Fock (HF)/6-31G** level and the single point energy was then calculated at the 
LMP2//6-31G** level.  All atoms were constrained during the geometry optimization 
except the adenine ring, the ribose C1´ atom and the ribose hydroxyl groups.  The anti 
conformation was generated from this truncated model by adjusting the O-C1´-N9-C4 
torsion angle to -140° followed by geometry optimization as described above.  The 
partial charges after geometry optimization were obtained for each of atom. 
Stopped-Flow Experiments.  The stopped-flow experiments were performed 
using a KinTek Stopped-Flow apparatus (Model SF-2004, KinTek Corp., Austin, TX).  
Experiments were carried out at 25 °C in 10 mM HEPES, pH 7.5, 200 mM NaCl, and 
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1 mM DTT.  The time dependence of binding was measured by monitoring changes in 
the intrinsic protein fluorescence.  An excitation wavelength of 298 nm (rather than 
the excitation maximum of ~280 nm) was used to avoid problems associated with 
inner filtering caused by increasing the ligand concentration.  Emission was observed 
using a band-pass filter centered at 340 nm (± 10 nm).  All reported concentrations 
refer to the final value after rapidly mixing ligand with enzyme at a ratio of 1:1 (v/v).  
The final enzyme concentration was 25 µM for the WT protein, F7A and E247A 
mutants and 100 µM for the F223A mutant.  AdoMet was mixed with enzyme in at 
least a 4-fold excess in order to maintain pseudo-first order conditions.  Linear and 
nonlinear regression of the data were performed using GraFit 5 (Erithacus Software, 
Horley, Surrey, UK).
Figure Preparation.  Structural figures were generated using Pymol (31). 
Section 3.3. Results 
Cocrystallization of AdoMetDC with Ligands.  The enzyme was cocrystallized 
in the presence of SAH, MMTA, DMAMA and MTA.  The crystallization 
experiments show that only MMTA and DMAMA bound to the enzyme in the crystal 
while MTA and SAH did not.  Cocrystallization experiments for MTA and SAH were 
performed at increased concentrations and incubation times to increase the possibility 
of binding at the active site; however, no active site density was observed. 
Crystal Structure of AdoMetDC with MMTA.  The overall fold of AdoMetDC 
is a four-layer αββα sandwich as previously described (32).  AdoMetDC 
autoprocessing results in an α subunit with an N-terminal pyruvoyl group and a 
smaller β subunit (32, 33).  One molecule of putrescine is bound between the β sheets 
for each monomer and is located about 15-20 Å from the active site.  
In the crystal structure of AdoMetDC with MMTA, loops containing residues 
1-4, 22-26, 165-172, 288-299, 328-334 were disordered and were excluded from the 
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model.  MMTA ribose forms hydrogen bonds to Glu247; the O2´ - Oε2 distance is 3.2 
Å and the O3´ - Oε1 distance is 2.7 Å.  The sulfonium sulfur atom is 4.4 Å from the 
center of Phe233 ring and the closest contact of sulfur atom with Phe223 is 3.9 Å 
(Cε1).  The methylene carbon atom adjacent to the sulfonium ion of MMTA is 4.4 Å 
from the center of Phe7 and 3.6 Å from the Cε2 carbon of Phe7.  The glycosidic bond 
of MMTA adopts a syn conformation and the adenine ring stacks between Phe223 and 
Phe7.  The stereoview of the electron density for MMTA in the active site is shown in 
Figure 3.1.  
Crystal Structure of AdoMetDC with DMAMA.  In the structure of AdoMetDC 
with DMAMA the loops containing the residues 1-3, 24-26, 165-173, 288-299, 328-
334 were missing in the crystal structure.  The ribose makes two hydrogen bonds to 
Glu247 with the O2´- Oε2 distance being 2.9 Å and the O3´- Oε1 distance being 2.6 
Å.  The nitrogen is 4.7 Å from the center of Phe223 and 4.2 Å from the Cε1 atom of 
Phe223.  The methylene carbon atom adjacent to the nitrogen atom is at a distance of 
4.3 Å from the center of Phe7 and 3.7 Å from the Cε2 carbon of Phe7.  The adenosine 
moiety of DMAMA is in a syn conformation with the adenine base stacking between 
Phe7 and Phe223.  A stereoview of the electron density for DMAMA in the active site 
is shown in Figure 3.2. 
Quantum Mechanical Calculations.  The LMP2/6-31G** energies from the 
quantum mechanical calculations are shown in Table 3.3.  The calculated gas phase 
binding energy of (CH3)3S+ between two benzene rings in the same geometrical 
orientations as Phe7 and Phe223 is -5.09 kcal/mol.  On the other hand, the binding 
energy of (CH3)2S between two benzene rings in the same geometrical orientations as 
Phe7 and Phe223 is only -0.60 kcal/mol.  These calculations suggest that the cation-π 
interaction provides an addition stabilization of approximately -4.5 kcal/mol.  Similar 
calculations suggest that the binding energy of (CH3)3S+ to Phe223 is -3.15 kcal/mol  
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Figure 3.1.  Stereoview of the complex of MMTA with AdoMetDC.  The difference 
Fo-Fc Fourier density is contoured at 2.5σ.  The carbon atoms of the ligand are colored 
green.  The hydrogen bonds are shown as red dashed lines. 
 
 
Figure 3.2.  Stereoview of the complex of DMAMA with AdoMetDC.  The difference 
Fo-Fc Fourier density is contoured at 4σ.  The carbon atoms of the ligand are colored 
green.  The hydrogen bonds are shown as red dashed lines. 
 
and the binding energy to Phe7 is -3.41 kcal/mol. 
The ab initio energy of the syn conformation of MMTA in the complex with 
Phe223, Phe7 and Glu247 is -3039.28899965619 hartrees and the energy of the anti 
conformation is -3039.26998403002 hartrees.  Thus, the energy difference between 
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the syn and anti conformations of MMTA in the active site is -11.93 kcal/mol favoring 
the syn conformation.  This would represent the stabilization of the syn conformation 
caused primarily by Phe223 and Phe7. 
We also investigated the conformational energetics of MMTA and MTA in 
aqueous solution using quantum chemical calculations.  The results are in agreement 
with the experimental results described by Markham et al. (30)  These compounds 
prefer an anti conformation in aqueous solution.  The LMP2/cc-PVTZ(-f) //B3LYP/6-
31G* calculated energy difference between the anti and syn conformations was 1.06 
kcal/mol for MMTA and 0.88 kcal/mol for MTA favoring the anti conformation in 
each case.  
Table 3.3.  Quantum Chemical Energies of Residues / Ligands  
 
 Energy in hartrees 
Benzene -231. 47989407141 
(CH3)2S -477.13908367149 
(CH3)2S    +   Phe223   +  Phe 7 -940.10191861550 
(CH3)3S+  +   Phe223 -748.08525375049 
(CH3)3S+  +   Phe7 -748.08567703979 
(CH3)3S+ -516.60034059742 
(CH3)3S+   +   Phe223   +  Phe 7 -979.57032658617 
 
Stopped-Flow Experiments.  An intrinsic fluorescence change was observed 
when AdoMetDC was rapidly mixed with AdoMet.  However, when SAH was mixed 
with AdoMetDC, there was no significant change other than that determined to be due 
to photobleaching (compared to a control minus SAH).  This indicates that SAH 
binding is much weaker and/or produces no discernable conformational change.  The 
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signal when MMTA was mixed with AdoMetDC was also too weak to measure the 
kinetics of the binding reaction.  
Kinetic data of AdoMet binding to WT AdoMetDC along with the F223A, 
F7A and E247A mutants were collected.  For WT, F7A and E247A the data were best 
fit to a double exponential equation  
(F=A1e-lt + A2e-l2t + C) to yield the observed rates (l1 and l2) and amplitudes 
(A1 and A2) of the two phases at each concentration of AdoMet.  The concentration 
dependence of the fast and slow phases are plotted in Figure 3.  The fast phase 
exhibited a linear concentration dependence, and did not saturate.  The slow phase was 
approximately hyperbolic and saturated at relatively low concentrations.  The data are 
best described by a minimal model of two sequential steps: 
 
    k1        k2 
E + S ↔ EX ↔ EA 
     k-1       k-2 
 
According to this model, the fast phase of the reaction occurs at an observed rate 
approximately equal to the sum of all four intrinsic rate constants (34): 
 
λ1 ~ k1[S] + k-1 + k2 + k-2 
 
A linear fit of the fast phase (AdoMet binding to WT enzyme) results in a k1 = 0.136 ± 
0.005 µM-1s-1, k-1 = 33 ± 2 s-1 and k2 + k-2 = 3.7 ± 0.2 s-1.  Therefore, the dissociation 
constant (Kd) for AdoMet binding to AdoMetDC can be estimated to be 242 ± 17 µM 
from the ratio of k-1/k1.  
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Figure 3.3.  Plots of observed rate vs. [AdoMet] for the WT, F223A, F7A and E247A 
mutants.  The linear concentration dependence of the observed rates was fit using a 
line which allowed for the definition of k1 and k-1.  A hyperbolic fit of the slow phase 
defined the sum of k2 and k-2, except in the case of F223A, where the kinetics were 
monophasic and indicative of a more simple one step binding model.  In this case the 
slope of the best fit line defines the k1 and the y-intercept defines the k-1 directly. 
 
For the F7A and E247A mutants, the data were analyzed in a similar fashion 
except that a lower overall signal change caused photobleaching to become a 
significant component of the data.  Therefore, the decrease due to photobleaching was 
corrected by using data from a control reaction where substrate was omitted (resulting 
in a linear decrease in fluorescence).  After correction, the kinetic parameters were 
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obtained as for the WT enzyme.  The values of k-1 and k2 + k-2 were similar for both 
the mutants but the value of the second order rate constant for substrate binding (k1) 
changed significantly.  Based upon the values of k1 and k-1, the Kd for the F7A mutant 
was 370 ± 60 µM and the Kd for the E247A mutant was 12.2 ± 3.6 mM.  
The fluorescence change seen upon mixing AdoMet with the F223A mutant 
was best fit using a single exponential equation.  The concentration dependence of the 
observed rate varied linearly with a slope (k1) of 1.7 ± 0.3 × 10-4 µM-1s-1 and a y-
intercept (k-1) of 2.4 ± 0.2 s-1 yielding a Kd of 14 ± 3 mM.  Generally, the values 
measured here follow the same trend as the steady state kinetic parameters (kcat and 
Km) obtained previously (22).  A comparison of Kd values for AdoMet binding to WT, 
F223A, F7A, and E247A mutants reveals that the importance of residues for substrate 
binding follows the order F223A ~ E247A >> F7A > WT. 
Section 3.4. Discussion 
Cation-π Interactions and Ligand Specificity of AdoMetDC.  Cation-π 
interactions are ubiquitous in nature and aid in protein stability, ligand recognition, 
catalysis and ion channel function (35, 36).  In the gas phase, the binding energy of 
cations to aromatic groups ranges from 10-40 kcal/mol which places the cation-π 
interaction among the strongest noncovalent forces (35, 37).  The magnitude of the 
cation-π interaction depends on the geometry, distance and the nature of the cation and 
the aromatic group.  In biological systems, the bulk of these interactions are seen with 
the amino acid side chains of proteins.  Aromatic amino acids such as tryptophan, 
tyrosine and phenylalanine interact with positive charged amino acids such as lysine 
and arginine.  The energetics of these interactions have been studied both 
experimentally and theoretically (38, 39).  In a few cases, ligand recognition by an 
enzyme is attributed completely to the cation-π interaction (40).  It has been shown 
that AdoMetDC binds substrate analogues only if they have a positive charge at the 
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sulfonium position (20).  MHZPA and MAOEA, which do not contain a sulfonium 
center, have an ammonium group that is protonated at physiological pH.  The inability 
to form MTA and SAH complexes in cocrystallization experiments is consistent with 
this observation.  
The results reported here suggest that cation-π interactions play a primary role 
in determining substrate specificity.  The crystal structure of AdoMetDC with MMTA 
shows that the sulfonium center is at a favorable distance and geometry for a cation-π 
interaction with Phe223.  The positive charge of the sulfonium ion is distributed to the 
adjacent methyl and the methylene groups (Figure 3.4).  The methylene group of 
MMTA is at a favorable distance and geometry for a cation-π interaction with Phe7.  
The quantum chemical calculations suggest the stabilization of a (CH3)3S+ group in 
the active site is primarily due to its interaction with Phe223 and Phe7.  Other ligands 
with a positive charge such as MHZPA, MAOEA, MeAdoMet and DMAMA show 
similar interactions with Phe223 and Phe7 (Figure 3.5).  The magnitude of 
stabilization obtained due to the cation-π interaction is approximately -4.5 kcal/mol.  
The interaction may be weakened from its maximum value by distribution of positive 
charge to adjacent carbon and hydrogen atoms and because of non-ideal geometry. 
The cation-π interaction as a theme for sulfonium recognition was debated by 
Markham et al. based on a survey of the crystal structures of AdoMet with various 
enzymes (30).  The survey which spanned 20 crystal structures showed that the 
sulfonium of AdoMet interacts with negatively charged atoms and aromatic amino 
acids in very few cases.  In glycine-N-methyltransferase (PDB code 1xva) and HhaI 
DNA methylase (PDB code 1hmy), the sulfonium interacts with negatively charged 
carboxylate atoms (41, 42).  There are only two cases in the survey where the 
sulfonium ion has a close contact with an aromatic group.  The sulfonium ion of 
AdoMet is 3.2 Å from the methylene carbon atom of Trp41 in HhaI DNA methylase  
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Figure 3.4.  Schematic diagram of the key interactions MMTA makes in the active site 
of AdoMetDC.  The adenine base stacks in the syn conformation aided by aromatic 
stacking interactions to Phe7 and Phe223.  The N6 of the adenine base hydrogen 
bonds to the backbone carbonyl of Glu67.  The sulfonium ion and the terminal methyl 
group have a cation-π interaction with Phe223 (shown in red) and the partially 
positively charged methylene group adjacent to sulfonium interacts with Phe7.  The 
N3 atom is partially negative charged and interacts with the sulfonium.  The partial 
charges on the relevant atoms are indicated.  The ribose makes two hydrogen bonds to 
Glu247.  
 
(PDB code 1hmy) and in the structure of AdoMetDC with MeAdoMet bound (PDB 
code 1I7B) the sulfonium ion is located 4.1 Å from the center of Phe223.  The survey 
concluded that in a broader picture, cation-π interactions are not a recurring theme for 
sulfonium recognition.  However, the uniqueness of the AdoMet decarboxylation 
reaction in this study may explain the importance of cation-π interaction for 
AdoMetDC, which further is supported by theoretical calculations and stopped-flow 
kinetic experiments.
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Figure 3.5.  The superposition of the complexes of AdoMetDC showing the geometry 
of the cation-π interaction between the positive sulfonium / nitrogen with Phe223.  
The color coding for the complexes is as follows; MMTA, red; DMAMA, magenta; 
MeAdoMet, green; MAOEA, blue; MHZPA, yellow. 
 
Stabilization of the syn Conformation by AdoMetDC.  The conformational 
preference of AdoMet in solution and gas phase was studied by Markham et al. (30).  
According to the NMR studies, AdoMet prefers an anti conformation about the 
glycosidic bond in solution and a syn conformation in vacuum.  The energy difference 
between the anti and syn conformations in solution was calculated to be -34 kcal/mol 
based on the modeling studies using NMR constraints.  This energy difference was 
calculated based on molecular mechanics without polarization effects and it is likely 
that the actual difference is less negative (23).  The crystal structure of AdoMetDC 
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with MeAdoMet, MHZPA and MAOEA reported previously showed that the enzyme 
binds the ligands in the energetically unfavorable syn conformation (22). 
The crystal structures of AdoMetDC with MMTA and DMAMA also show 
that the adenosine moiety binds in a syn conformation.  The quantum chemical 
calculations for MMTA in a truncated model of the enzyme with only Phe7, Phe223 
and Glu247 included suggest that the syn conformation of the ligand is stabilized by 
~12 kcal/mol compared to hypothetical anti conformation, which has never been 
observed in an AdoMetDC complex.  The actual energy difference is likely to be 
greater than the above value since the anti conformation places the six-membered ring 
of the adenine in close proximity to Asn224 and Pro225.  Moreover, the amino group 
on the adenine ring is in close proximity and makes hydrogen bonds to Glu67 in the 
syn conformation but forms no appreciable interactions with the enzyme in the anti 
conformation.  
The syn conformation of the adenine base is primarily stabilized by stacking 
interactions with Phe7 and Phe223 and hydrogen bonds of the ribose to Glu247.  The 
N3 atom of the adenine base carries a partial negative charge and interacts favorably 
with the sulfonium ion.  This electrostatic effect further contributes in stabilizing the 
syn conformation of the ligand.  The preference of AdoMetDC to bind ligands in the 
syn conformation was recently exploited in the design of substrate analogues with 
enhanced affinity.  Substitution at the C8 position on the adenine base favored the syn 
conformation resulting a 5-18 fold increase in potency compared to the unsubstituted 
compounds (23). 
Insights into Inhibitor Design.  The design of substrate analogue inhibitors for 
AdoMetDC benefit from the presence of a positive charge required for the cation-π 
interaction.  Unlike MAOEA and MHZPA, MMTA shows competitive inhibition 
because it lacks an amino terminus required to form a Schiff base with the active site 
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pyruvoyl group.  Studies on MMTA also show that the ribose, adenine base and the 
positive charge are sufficient for inhibition of AdoMetDC.  The schematic diagram 
showing all of the stabilizing interactions of MMTA in the active site is shown in 
Figure 3.4.  
The MMTA analog, DMAMA shows that the replacement of the sulfur by 
nitrogen also yields a competitive inhibitor because the nitrogen is protonated at 
physiological pH.  DMAMA has a methyl substitution at the 8-position which should 
favor the syn conformation in solution and improve the binding to AdoMetDC (23).  
Because MMTA and DMAMA lack hydrazino or oxyamino groups, which react 
nonspecifically with cellular aldehydes and ketones, and because further evolution of 
their structures are possible, MMTA and DMAMA, with IC50 values of 15 µM and 
600 nM (23), respectively, are promising lead compounds for inhibitor design. 
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CHAPTER 4 
NEW INSIGHTS INTO THE DESIGN OF INHIBITORS OF HUMAN S-
ADENOSYLMETHIONINE DECARBOXYLASE: STUDIES OF ADENINE C8 
SUBSTITUTION IN STRUCTURAL ANALOGUES OF S-
ADENOSYLMETHIONINE3 
Section 4.1. Introduction 
S-Adenosylmethionine decarboxylase (AdoMetDC) is a pyruvoyl dependent 
decarboxylase and a critical enzyme in the polyamine biosynthetic pathway, which is 
found in mammals, Protista and many other species (1-4).  The polyamines 
putrescine, spermidine and spermine are essential for cell growth and play important 
roles in cell proliferation and differentiation (5-7).  Polyamines have been found to be 
elevated in various types of cancer including non small cell lung cancer, prostate 
cancer, melanoma, and pancreatic cancer (8, 9).  Polyamine levels in cells depend on 
the polyamine biosynthetic and catabolic pathways as well as on import and export of 
polyamines across the cellular membrane.  Altering regulation of the key enzymes in 
the polyamine pathway is a therapeutic strategy for treatment of various types of 
cancers.  AdoMetDC catalyzes the conversion of S-adenosylmethionine (AdoMet) to 
decarboxylated S-adenosylmethionine (dcAdoMet), which then donates the 
aminopropyl group to putrescine or spermidine to form spermidine and spermine, 
respectively.  AdoMetDC is at a key branch point in the pathway and its action 
commits AdoMet to polyamine biosynthesis and removes it from the pool available 
for methyl transfer to a variety of substrates. 
                                                
3 Reproduced in part with permission from McCloskey DE, Bale S, Secrist III JA, Tiwari A, Moss III 
TH, Valiyaveettil J, Brooks WH, Guida WC, Pegg AE, Ealick SE. (2009) J. Med. Chem. 52(5) 1388-
1407 Copyright 2009 American Chemical Society 
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Attempts to regulate polyamine levels have resulted in the development of 
inhibitors that target the biosynthetic enzymes ornithine decarboxylase (ODC) (10), 
AdoMetDC and the catabolic enzyme spermidine/spermine N1-acetyltransferase 
(SSAT) (11).  The best-known inhibitor of ODC is α-difluoromethylornithine 
(DFMO), which irreversibly inactivates the enzyme.  The success of DFMO in cancer 
therapy has been limited as the cells compensate for the decreased synthesis of 
polyamines through increased cellular uptake of polyamines (12).  DFMO is currently 
being investigated as a chemopreventive agent against carcinogenesis (13-17).  The 
development of drugs to inhibit AdoMetDC (Figure 4.1 A) started with the 
competitive inhibitor methylglyoxal bis(guanylhydrazone) 1 (MGBG), which is 
similar to spermidine in structure (18).  Use of MGBG 1 caused extreme toxicity in 
humans and many analogues of MGBG 1 were developed in attempts to decrease the 
toxicity.  One such AdoMetDC inhibitor that resulted was 4-amidinoindan-1-one-2′-
amidinohydrazone 2 (CGP48664A), which progressed into clinical trials as a cancer 
chemotherapeutic agent (19).  Alternatively, inhibitors such as 5′-deoxy-5′-[(3-
hydrazinopropyl)methylamino]adenosine 3 (MHZPA), 5′-deoxy-5′-[(3-
hydrazinoethyl)methylamino]adenosine 4 (MHZEA) and 5′-[(2-
aminooxyethyl)methylamino]-5′-deoxyadenosine 5 (MAOEA) that are structural 
analogues of the natural substrate were developed (Figure 4.1 B).  These compounds 
inactivate AdoMetDC by forming a Schiff base to the active site pyruvoyl group (20).  
Another known nucleoside inhibitor of AdoMetDC is 5′-[[(Z)-4-amino-2-
butenyl]methylamino]-5′-deoxyadenosine.  This butenyl analogue was designed as an 
enzyme-activated irreversible inhibitor (21) but subsequent experiments showed that it 
acted via transamination of the pyruvate prosthetic group (20). 
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Figure 4.1: Previously described inhibitors of hAdoMetDC 
The crystal structure of AdoMetDC and its S68A and H243A mutants were 
solved to aid understanding of the mechanisms of decarboxylation and autoprocessing 
(22-24).  The crystal structures of AdoMetDC with inhibitors such as MAOEA 5, 
MHZPA 3 and the methyl ester of S-adenosylmethionine (MeAdoMet) also have been 
solved previously (25).  These structures show that the adenine base of the inhibitors 
assumes an unusual syn conformation within the active site.  The preference for the 
unusual conformation has led us to develop new structural analogues of AdoMet with 
modifications on the adenine base and to investigate, through biochemical analysis, 
computational modeling, and analysis of crystal structures, whether these compounds 
would be more potent inhibitors of AdoMetDC than the unsubstituted parent 
compounds.  Substitution at the 8-position of adenine is expected to result in ligands 
that favor the syn conformation in solution, and it was hoped that this would increase 
their ability to inhibit AdoMetDC.  We now describe the synthesis of several series of 
structural analogues of AdoMet with 8-substituted adenine and present AdoMetDC 
inhibition data.  We report the crystal structures of the AdoMetDC F223A mutant 
complexed with MeAdoMet and the wild-type protein complexed with several 8-
substituted inhibitors. 
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Section 4.2. Materials and Methods 
Target Synthesis.  TLC analysis was performed on Analtech precoated (250 
µm) silica gel GF plates.  Melting points were determined on a Mel-Temp apparatus 
and are uncorrected.  Purifications by flash chromatography were carried out on 
Merck silica gel (230-400 mesh).  Evaporations were performed with a rotary 
evaporator, higher boiling solvents (dimethylformamide (DMF), pyridine) were 
removed in vacuo (<1 mm, bath to 35 °C).  Products were dried in vacuo (<1 mm) at 
22-25 °C over P2O5.  The mass spectral data were obtained with a Varian-MAT 311A 
mass spectrometer in the fast atom bombardment (FAB) mode or with a Bruker 
BIOTOF II by electrospray ionization (ESI). 1H NMR spectra were recorded on a 
Nicolet NT-300 NB spectrometer operating at 300.635 MHz.  Chemical shifts in 
CDCl3 and Me2SO-d6 are expressed in parts per million downfield from 
tetramethylsilane (TMS) and in D2O chemical shifts are expressed in parts per million 
downfield from sodium 3-(trimethylsilyl)propionate-2,2,3.3-d4 (TMSP).  Chemical 
shifts (δ) listed for multiplets were measured from the approximate centers, and 
relative integrals of peak areas agreed with those expected for the assigned structures.  
UV absorption spectra were determined on a Perkin-Elmer Lambda 19 spectrometer 
by dissolving each compound in MeOH or EtOH, and diluting 10-fold with 0.1 N 
HCl, pH 7 buffer, or 0.1 N NaOH.  Numbers in parentheses are extinction coefficients 
(ε x 10-3).  Microanalyses were performed by Atlantic Microlab, Inc. (Atlanta, GA) or 
the Spectroscopic and Analytical Department of Southern Research Institute.  
Analytical results indicated by element symbols were within ±0.4% of the theoretical 
values, and where solvents are indicated in the formula, their presence was confirmed 
by 1H NMR. 
Chemical Synthesis.  Our synthetic efforts relating to AdoMetDC date back 
many years, when we prepared an early series of related compounds that included 
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MHZPA 3 and MAOEA 5 (26).  In our current research, we have prepared a series of 
compounds with various 8-substituents on an adenosine template having a chain 
extension at C-5′.  These compounds fall into four broad categories with respect to the 
various substituents at C-5′, and synthetic schemes will be organized based upon these 
categories.  For comparison purposes, we have included available compounds with an 
8-H within the four categories.  End groups of the C-5´ substituent such as an 
aminooxyalkyl will bind covalently and to a large extent irreversibly to the pyruvoyl 
group within the active site of the enzyme, while groups ending in an amide will not 
even bind reversibly to the pyruvoyl group.  Amino end groups will bind covalently, 
but entirely reversibly, while a hydrazide group binds with some reversibility.  In 
addition to these compounds we have prepared several compounds without a chain 
extension at C-5′, i.e., compounds that do not reach the vicinity of the pyruvate group 
within the binding site. 
The syntheses of some of the 8-unsubstituted compounds date back to our 
earlier work (26), and these compounds dictated our initial synthetic approaches.  We 
began by assuming that we needed to block the 2′- and 3′-hydroxyl groups, which we 
did with an isopropylidene group.  Later, we discovered that it was possible to conduct 
the chemistry without blocking these two hydroxyl groups, and that the new schemes 
were superior to those that utilized a blocking-deblocking sequence.  In situations 
where we had already prepared a target compound utilizing a blocked precursor, we 
did not go back and resynthesize the compound without using a blocking group, and 
the schemes below reflect that fact.  Figure 4.2 presents the precursor nucleoside series 
8 and 9 that we have used along with their syntheses. 
Target compounds with an aminooxyalkylamino side chain at C-5′ were 
prepared using two different routes, as shown in Figure 4.3.  In our original sequence, 
which utilized a 2′,3′-O-isopropylidene group for protection, we generated the 
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hydroxyalkylamino precursor 15 by displacement of a tosyl group with the requisite 
amine.  Using N-hydroxyphthalimide, triphenylphosphine and DEAD (27) the 
aminooxy precursor 16 was produced and then converted to the desired target 5 under 
acidic conditions.  Later we found that it was more effective to first generate the 
aminooxy precursors ethyl N-(2-bromoethoxy)ethanimidate (28) and ethyl N-(N-4-
bromobutoxy)ethanimidate (29), which could be appended to C-5′ by halide 
displacement with a 5′-methylamino-5′-deoxynucleoside to produce product series 11 
and 13.  Initially we carried out this displacement with an isopropylidene protecting 
group on the nucleoside, but subsequently determined that the reaction works as well 
or better without the protecting group.  By the above means targets 12a-c and 14a-f 
were prepared. 
All of the amides and hydrazides were made by similar procedures, as shown 
in Figure 4.4.  The 5′-methylamino-5′-deoxynucleosides were treated with the 
appropriate ω-chloroester followed by treatment with either ammonia or hydrazine.  If 
an isopropylidene group was involved, then it was removed with an acidic 
deprotection step.  In this manner targets 17d-f, j-m, with two different linker lengths 
and various 8-substitutions were prepared.  Targets with an aminoalkylamino side 
chain at C-5′ were mainly prepared utilizing the displacement of a C-5′ leaving group 
with the asymmetrical amine (Figure 4.5).  For example, treatment of 8a with 3-
methylaminoethylamine produced a mixture of 18f and 19d, which were separated to 
afford pure 18f, our desired target.  In the case where this procedure involved a 
starting material with an isopropylidene group, treatment with acid produced the 
desired final product.  In early work, compounds 21c,d were prepared by treatment of 
a 5′-methylamino-5′-deoxynucleoside with 3-bromopropylphthalimide followed by 
two deprotection steps. 
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Figure 4.2 Synthetic scheme for new inhibitors – part I. (a) (CH3)4Sn or (CH3CH2)4Sn, 
HMDS/dioxane, NMP, (Ph3P)4Pd, 110 °C; (b) CH3NH2, MeOH, 110 °C; (c) 
C6H5B(OH)2, K2CO3, (Ph3P)4Pd, 1,2-DME-H2O (2:1), 90 °C; (d) SOCl2, 
CH3CN/pyridine, 0 °C-RT, NH4OH, RT; (e) MsCl, pyridine, 0 °C; (f) 33% CH3NH2, 
EtOH, RT (9e,f,g) or 90 °C (9a-d); (g) NaOMe/MeOH, RT 
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Figure 4.3 Synthetic scheme for new inhibitors – part II.  
(a) CH3(OEt)C=NO(CH2)2Br, DMF, DIEA, 50 °C; (b) 1 N H2SO4, RT; (c) 
CH3(OEt)C=NO(CH2)4Br, DMF, DIEA, 50 °C; (d) 2-(methylaminoethanol), RT; (e) -
hydroxyphthalimide, PPh3, DEAD, THF, RT; (f) 1 N H2SO4, 60 °C.  
 
 
 
Figure 4.4 Synthetic scheme for new inhibitors – part III. (a) Cl(CH2)nCO2Et (n = 1 or 
2), DMF, DIEA, 60 °C; (b) NH3/MeOH, RT; (c) 1 N H2SO4, RT; (d) NH2NH2, H2O, 
EtOH, reflux.  
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Figure 4.5 Synthetic scheme for new inhibitors – part IV. (a) CH3NH(CH2)nNH2 (n = 
1 or 2), RT; (b) 1 N H2SO4, RT; (c) 3-bromopropylphthalimide, DMF, DIEA, 60 °C; 
(d) NH2NH2, H2O, reflux; (e) 1H- pyrazole-1-carboxamidine · HCl, DMF, DIEA, RT; 
(f) 3-(methylamino)propionitrile, RT; (g) NH2OH · HCl, MeOH, DMF, KOH, RT. 
 
Figure 4.6 Synthetic scheme for new inhibitors – part V. (a) (CH3)2NH, 2 M solution 
in MeOH, 90 °C; (b) CH3SNa, DMF, RT; (c) CH3Br, Et2O, HCO2H, HOAc, RT; (d) 
IRA-400 (Cl) ion exchange resin. 
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Building on the aminoalkylamino side chain, reaction of 18e with 1-
carboxamidinopyrazole (30) produced the guanidine target 22a.  In a related sequence, 
the target amidoxime 22c was prepared by treating 8j with 3-
(methylamino)propionitrile to produce the nitrile 22b (31), which was treated with 
hydroxylamine hydrochloride under basic conditions. 
The 5′-dimethylamino and 5′-dimethylsulfonio compounds 23a,b and 25a-d 
were prepared by routine methods (Figure 4.6).  The dimethylamino group was 
introduced by displacement of a 5′-chlorine on 8a or 8g (32) with dimethylamine.  The 
5′-methylthio compounds 24a,b were treated with methyl bromide to produce 25a and 
25c.  Ion exchange was utilized to prepare the chloride salts 25b and 25d. 8-Methyl-
5′-methylthio nucleoside 24a was prepared by displacement of the 5′-chlorine in 8a 
with sodium thiomethoxide. 
Protein Production.  For crystallography of wild type and F223A mutant of 
human AdoMetDC (hAdoMetDC), plasmids in the pQE30 vector in E. coli were 
produced as described previously (25).  This construct replaces the N-terminal 
methionine with MRGS(H)6GS- for purification by immobilized metal affinity 
chromatography.  A different plasmid also based on the pQE30 vector was used for 
the production of protein for the hAdoMetDC enzyme assays.  In this plasmid, the 
(H)6 tag was located at the carboxyl end replacing the terminal –QQQQQS.  The 
position of the (H)6 tag did not alter the activity of the purified enzyme. 
The wild type hAdoMetDC was purified based on the protocol described by 
Ekstrom et al. (22).  The plasmid encoding the enzyme is in the pQE30 vector and was 
transformed into JM109 strain E. coli cells.  The cells were grown as an overnight 
culture in LB media at 37 °C and then introduced into larger cell cultures with both of 
the cultures containing 100 mg/mL ampicillin.  The cells were grown until they 
reached an O.D600 of 0.6 and then were induced with 100 mg/L isopropyl β-D-
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thiogalactopyranoside (IPTG).  The cells were allowed to grow overnight at 15 °C and 
were then harvested by centrifugation, washed using a wash buffer which contained 20 
mM Na2HPO4, pH 7.0, 500 mM NaCl, 2.5 mM putrescine, 0.02% Brij-35 and 10 mM 
imidazole, and stored at -80 °C.  The frozen cell pellet was thawed, suspended in the 
wash buffer, and lysed using a French press at 1500 psi.  The cellular debris and the 
lysate were separated by centrifugation at 12000 g.  Talon metal affinity resin was 
equilibrated with the wash buffer and then the lysate and the resin were gently spun 
together for 1.5 h.  The resin was loaded onto a column and washed with a volume of 
wash buffer equivalent to 15-20 times the column volume.  Next, the column was 
washed in the same manner with wash buffer containing 25 mM imidazole.  The 
protein was then eluted with buffer containing 100-200 mM imidazole.  The eluted 
protein solution was concentrated to around 10 mL and passed through a Sephadex G-
75 column pre-equilibrated with 10 mM N-(2-hydroxyethyl)piperazine-N′-2-
ethanesulfonic acid (HEPES), pH 7.5, 2.5 mM putrescine, 5 mM dithiothreitol (DTT), 
0.1 mM ethylenediaminetetraacetic acid, 0.02 % Brij-35, and 300 mM NaCl.  The 
buffer was run through the column and the fractions containing the protein were 
identified by UV absorbance at 280 nm.  The protein was concentrated to ~ 10 mg/mL 
and stored at -80 °C.  The purification of the F223A mutant was similar to that of the 
native enzyme. 
Structure Determination.  The protein was thawed on ice and buffer exchanged 
to 10 mM HEPES, pH 7.5, 200 mM NaCl and 1 mM DTT using Bio-Rad buffer 
exchange chromatography columns (Bio-Rad Laboratories, Hercules, CA 94547).  The 
wild type protein was incubated with a 4-6 M excess of inhibitor for 24 h prior to 
crystallization.  The F223A mutant was diluted to ~6 mg/mL and incubated with a 4-6 
M excess of MeAdoMet for 24 h prior to crystallization.  Crystals of both the native 
and the mutant complexes were grown using the hanging drop method at 22 °C in 13-
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16% PEG 8000, 100 mM Tris, pH 8.0-9.0, and 10 mM DTT.  Crystals appeared 
overnight and were stable for 1-2 weeks. 
The data for the 12a complex were collected at a home source with a Rigaku 
R-AxisIV++ image plate detector using Cu-Kα radiation from a Rigaku RU-300 
rotating anode generator.  The data for the 14e complex were collected at NE-CAT 
beamline 8-BM at the Advanced Photon Source (APS) using a ADSC Q315 detector.  
Data for the 17f complex were collected at NE-CAT beamline 24-ID-C using a ADSC 
Q315 detector.  The data for AdoMetDC F223A with MeAdoMet and the complexes 
with 17d and 21c were collected at the F2, A1 and A1 stations of CHESS respectively, 
using an ADSC Q210 detector.  The diffraction quality of the crystals strongly 
depended on cryoprotection conditions.  The crystals were sequentially transferred to a 
solution containing the well solution with 2%, 5%, 8%, 15% and 18% glycerol with 1-
2 min equilibration between each step.  The data for all of the complexes were 
indexed, integrated and scaled using the HKL2000 (33) program suite.  The data 
collection statistics are summarized in Table 4.1. 
The structures of all of the complexes were determined by molecular 
replacement using the structure of native AdoMetDC with MeAdoMet bound (PDB 
1I7B) as the search model, and the CNS program suite (34).  The model building was 
done using the program O (35) or Coot (36).  The conformations of the ligand 
molecules were determined using difference Fo-Fc and composite omit maps.  The 
parameter and the topology files for the ligands were generated using the HIC-Up 
server (37).  The difference maps also showed density for a molecule of putrescine 
bound in all of the structures.  The refinement statistics of the complexes are given in 
Table 4.2. 
Molecular Modeling.  Determination of the conformational preference of 
ligands in the active site of AdoMetDC was carried out with Macromodel version 7.2 
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(38) available from Schrödinger, L. L. C.  To make the computational studies 
tractable, the protein was truncated to a shell of atoms that included any residue that 
contained an atom within 20.0 Å of MeAdoMet located in the active site of 
AdoMetDC (from PDB 1I7B) and was used as the starting model for conformational 
searching/energy minimization.  Removal of water molecules from this “docking 
shell” was followed by appropriate hydrogen treatment using Schrödinger’s protein 
preparation utility that aids in the generation of appropriate ionic states and histidine 
tautomers for active site amino acids and minimizes the protein’s potential energy 
gradient through a series of constrained energy minimizations.  For the conformational 
searches, the appropriate ligand was added to the active site and, where appropriate, 
the covalent bond between the amino terminus of the ligand and the pyruvoyl group 
was formed. 
The resulting structures were subjected to 50,000 mixed Monte Carlo 
MCMM/Low Mode conformational search steps (39, 40) allowing residues within a 5 
Å shell surrounding the active site to move freely during each Monte Carlo/Low Mode 
step and subsequent energy minimization step of the search.  All other protein atoms 
were constrained to their starting position.  Residues His5, Glu67, Cys226 and Glu247 
were also constrained to their starting position.  The energy minimization step was 
considered to have converged when the energy gradient was less than 0.05 kJ / mol.  
The AMBER* force field (41, 42), with a distance dependent dielectric “constant” 
further attenuated by a factor of four was employed for the calculations, and the 
energy minimizations relied upon the TNCG minimization technique (43).  The global 
minimum and low energy ensemble of structures within 15 kJ/mol of the global 
minimum (after convergence) were further refined by energy minimization until a 
gradient less than 0.01 kJ / mol was obtained with just the ligand allowed to move 
during this subsequent energy minimization procedure.  All protein atoms during this 
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process were constrained to their starting position.  The jobs were run with the 
nucleoside starting in both the syn and anti conformations for completeness.  The 
AMBER* parameters for the sulfonium ion were adapted from Markham et al. (44). 
The modeling of the terminal three atoms of 14e was done using 
conformational searching with Macromodel version 7.2 as described above.  Since the 
position of the rest of the ligand and the protein was determined to high accuracy by 
fitting to the electron density determined by X-ray diffraction, all of the protein and 
the ligand atoms except the last three non-hydrogen atoms and their attached 
hydrogens were fixed during the conformational search.  Torsional rotation was 
allowed around the last two bonds of the C-5' extension during the conformational 
search.  A visual survey of the five lowest energy structures, which spanned an energy 
range of 6.5 kJ/mol, showed that they were similar and the global minimum of the 
search was utilized to obtain the coordinates of the disordered terminal atoms of 14e. 
AdoMetDC Activity and Inhibition.  AdoMetDC was assayed by measuring the 
release of 14CO2 from S-adenosyl-L-[carboxy-14C]methionine (Amersham Pharmacia 
Biotech, ~60 mCi/mmol) (45). Assay of 30 ng of C-terminal his-tagged AdoMetDC 
under these conditions results in ~7000 cpm with a background of 30, and an activity 
of ~1.5 pmol/min/ng protein.  For determination of the abilities of compounds to 
inhibit AdoMetDC, the enzyme activity was determined in the presence of no inhibitor 
and at least 5 concentrations of each potential inhibitor.  The enzyme concentation was 
1 nM.  The IC50 values were determined from curve fitting to plots of the inhibitor 
concentration versus the % inhibition of AdoMetDC.
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 Table 4.1.  Data collection statistics for hAdoMetDC complexes. 
 
 F223A + 
MeAdoMet 
WT + 
12a 
WT + 
14e 
WT + 
17d 
WT +  
17f 
WT + 
21c 
Wavelength 
(Å) 
0.9795 1.5418 0.9795 0.9790 0.9792 0.9771 
Space Group 
(Å) 
C2 C2 C2 C2 C2 C2 
a (Å) 95.98 96.78 94.43 99.82 99.65 100.08 
b (Å) 44.25 44.46 50.04 50.95 50.75 50.75 
c (Å) 70.83 70.55 70.41 68.98 68.90 69.04 
β 104.52 104.17 105.34 105.52 105.34 105.56 
Resolution 
(Å) 
2.62 2.43 1.83 1.84 1.91 1.86 
Total/Unique 
reflections 
23532/ 
8160 
26010 
/10403 
83134/ 
26894 
89749/ 
28243 
97188/ 
25449 
77769/ 
27505 
Redundancy 2.9(2.6)* 2.5 (1.9) 3.1(3.1) 3.2(2.6) 3.8(2.6) 2.8(2.5) 
% complete 92.9(91.2) 93.6(86.8) 95.6(95.5) 97.6(94.1) 98.8(91.0) 98.7(96.8) 
I/σ 13.3(2.0) 10.9(2.9) 13.5(2.7) 17.4(8.0) 16.6(3.9) 14.2(2.2) 
Rsym 7.7(45.2) 9.0(33.8) 7.2(54.8) 6.0(14.0) 7.6(25.0) 7.1(39.1) 
Matthews no 1.90 1.92 2.09 2.21 2.19 2.21 
Solvent 
content (%) 
34.1 34.8 39.7 43.2 42.9 43.2 
* Values in parenthesis are for the highest resolution shell. 
Rsym=ΣΣi|Ii - <I> | /Σ<I>, where <I> is the mean intensity of the N reflections with 
intensities Ii  and common indices h,k,l. 
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Table 4.2.  Refinement statistics for hAdoMetDC complexes. 
 F223A + 
 MeAdoMet 
WT + 
12a 
WT + 
14e 
WT + 
17d 
WT + 
17f 
WT + 
21c 
Resolution (Å) 2.62 2.43 1.83 1.84 1.91 1.86 
R-factora 0.203 0.199 0.208 0.204 0.197 0.200 
R-freeb 0.280 0.247 0.231 0.237 0.208 0.232 
No of non-H atoms       
Protein 2473 2419 2381 2489 2454 2470 
Ligand 28 25 28 26 25 25 
Water 79 73 137 222 212 217 
B-factors       
Protein (Å2) 41.3 31.5 29.6 26.8 28.2 32.4 
Ligand (Å2) 63.4 42.1 32.3 26.0 43.9 39.9 
Putrescine (Å2) 32.4 27.9 40.0 22.4 24.7 29.8 
rms deviations       
Bonds (Å) 0.010 0.011 0.007 0.006 0.012 0.008 
Angles (º) 1.4 1.4 1.3 1.3 1.4 1.3 
Dihedrals (º) 24.9 25.2 25.3 25.3 25.8 25.2 
Ramachandran plot       
Most favored region (%) 84.2 89.3 91.4 91.8 92.1 92.5 
Additional favored 
region (%) 
14.7 9.5 7.8 7.8 7.5 7.5 
Generously allowed 
region (%) 
0.8 0.8 0.4 0.4 0.4 0.0 
Disallowed region (%) 0.4 0.4 0.4 0.0 0.0 0.0 
 
aR-factor = Σhkl||Fobs|-k|Fcal||/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated 
structure factors, respectively.  In bR-free the sum is extended over a subset of 
reflections that were excluded from all stages of refinement. 
  98 
 Section 4.3. Results 
Modeling of MeAdoMet in the active site of AdoMetDC.  The crystal structures 
of AdoMetDC complexed with MeAdoMet or the inhibitors MHZPA 3 and MAOEA 
5 have shown that the ligand binds with the adenine base in the unusual syn 
conformation (25).  The active site residues of AdoMetDC with MeAdoMet bound are 
shown in Figure 4.7.  However, NMR data, coupled with molecular modeling studies, 
suggest that in solution AdoMet assumes an anti conformation as an energy minimum 
(44).  A survey of crystal structures in which AdoMet is bound showed that the 
substrate assumes a range of glycosidic torsion angles, but that the anti conformation 
is preferred (44).  In order to explain the conformational preferences and the related 
energetics of ligand binding to AdoMetDC, the modeling of MeAdoMet in the active 
site of AdoMetDC was done.  Since MeAdoMet is tethered to the active site of 
AdoMetDC through covalent bonding to the pyruvoyl group, docking involving 
positional and orientational sampling was not performed.  Instead, a conformational 
search to locate the populated low energy conformations of AdoMet in the AdoMetDC 
active site was performed using the mixed Monte Carlo/Low Mode conformational 
search method within the MacroModel program (38-40).  The conformational search 
started with AdoMet in either the anti or syn conformation and in each case the five 
lowest energy structures from the search exhibited a syn conformation for the adenine 
nucleoside.  A superposition of the modeled structure with the crystal structure (Figure 
4.7) indicates that the results of the conformational search match well with those 
observed crystallographically.  Conformational searches were also done for AdoMet, 
5′-deoxy-5′-(dimethylsulfonio)adenosine (MMTA), MHZPA 3, and MAOEA 5 
binding to AdoMetDC, and each yielded a syn conformation for the glycosidic bond 
(data not shown).  The ribose makes key hydrogen bonds to Glu247 and the adenine 
base stacks between Phe7 and Phe223 and also makes hydrogen bonds to the 
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backbone amide and C-terminal carboxyl group of Glu67.  These interactions together 
with π-π stacking of the adenine base with Phe223 and with Phe7 constrain the 
glycosidic bond to the syn conformation 
   
 
Figure 4.7 Comparison of the crystal structure of hAdoMetDC complexed with 
MeAdoMet to that of a structure derived from the modeling of the complex.  The 
crystal structure has all atoms colored grey. For the model, the active site pyruvoyl 
group is shown in magenta and MeAdoMet carbon atoms are shown in green.  
MeAdoMet makes a Schiff base to the pyruvoyl group.  The ribose makes two 
hydrogen bonds to Glu247 (shown as red dashed lines).  The adenine base stacks 
between Phe223 and Phe7 in the unusual syn conformation.  The hydrogen bonds 
between the adenine base and the backbone of Glu67 stabilize the syn conformation.  
The modeling result agrees well with the experimentally determined crystal structure. 
 
Virtual mutations in the active site of AdoMetDC.  Virtual mutations were 
made to study the effect of various residues on the conformation of the bound 
nucleoside.  Conformational searching with MacroModel employing the AdoMetDC 
F223A and F7A single amino acid mutants, with MeAdoMet in the active site, 
resulted in a mixture of syn and anti conformations in the low energy ensemble.  With 
each of the mutations, the global minimum was an anti conformation of the adenine 
base closely followed by a syn conformation with an energy difference of ~2 kJ/mol.  
The global minimum energy conformation of the ligand bound in the anti 
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conformation in the F223A mutant exhibits major changes compared to the 2nd lowest 
energy conformer which adopts the syn conformation.  In the F223A binding site, the 
ribose of the global minimum energy structure is displaced and makes hydrogen bonds 
to Glu247 and Cys226 instead of to Glu247 alone (Figure 4.8 A).  This change causes 
the ligand to twist back upon itself, the sulfonium stacks over the adenine base, and 
the adenine base makes three hydrogen bonds to Ser66.  In the F7A binding site, the 
ligand assumes a similar conformation as with the F223A mutant.  The Phe223 side 
chain undergoes a torsional change to accommodate the conformational change of the 
ligand and also stacks with the adenine base (Figure 4.8 B).  The presence of the anti 
conformation in low energy structures of the ligand in the enzyme active site where 
virtual mutations have been made suggests the importance of the phenyl groups in 
maintaining the syn conformation of the ligand within the wild-type enzyme binding 
site.  However, since we observed a syn conformation of the nucleoside as the 2nd 
lowest energy structure in our conformational search on the F223A mutant and since 
the relative energy of that structure compared to the global minimum ( E = 2.5 
kJ/mol) is well within the error limit of our calculations, we were prompted to obtain 
the crystal structure of the F223A mutant complexed with MeAdoMet. 
Structure of F223A Complexed with MeAdoMet.  The structure of the F223A 
mutant is similar to that of the wild type protein (22).  The human AdoMetDC 
protomer has a four layer αββα fold in which two β-sheets are sandwiched between 
two layers of α-helices.  The secondary structural elements are related by a pseudo 
twofold axis suggesting that the protomer resulted from gene duplication.  The 
proenzyme consists of 334 amino acid residues and the enzyme undergoes 
autoprocessing to give the α and the β subunits (22).   
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Figure 4.8 Comparison of modeling of hAdoMetDC F223A and hAdoMetDC F7A 
each complexed with MeAdoMet with the crystal structure of F223A mutant with 
MeAdoMet bound. Global minimum of modeling of MeAdoMet in the active site of 
the F223A mutant superposed with the crystal structure (A) and the F7A mutant (B) of 
hAdoMetDC (see Materials and Methods for details).  The crystal structure has all 
atoms colored grey. The pyruvoyl group is shown in magenta and the ligand carbon 
atoms are shown in green for the models.  Hydrogen bonds are shown as dashed lines.  
The adenine base attains an anti conformation in the models.  The ribose makes one 
hydrogen bond to Glu247 and the other to the backbone carbonyl of Cys226.  The 
adenine base makes three hydrogen bonds to Ser66.  In the F7A model (B) the Phe223 
residue changes its conformation to stack with the adenine base of MeAdoMet in the 
anti conformation. 
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The autoprocessing reaction yields the active enzyme with the pyruvoyl 
cofactor.  The pyruvoyl group is located at the end of the N terminal β-sheet and the 
active site involves residues from both of the β-sheets.  The binding site of putrescine, 
which activates both the autoprocessing and decarboxylation reactions of 
hAdoMetDC, is located well away from the ligand binding site within the wild-type 
enzyme.  Experimental conditions for the purification of the enzyme included 
putrescine at sufficient concentration to ensure high occupancy of the putrescine 
binding site.  The loops between the residues 1-4, 21-27, 165-173, 288-299, 329-334 
are disordered in the crystal structures.   
The crystal structure of hAdoMetDC F223A complexed with MeAdoMet was 
solved using molecular replacement.  The difference Fo-Fc density shows that 
MeAdoMet is covalently bound to the enzyme and the nucleoside adopts a clear syn 
conformation (Figure 4.8 A).  As expected, the composite omit map density shows no 
density for the Phe223 side chain.  The ribose makes two hydrogen bonds to Glu247, 
which anchor the ligand, and the base is held in syn conformation by stacking 
interactions with Phe7 and hydrogen bonds between the adenine and Glu67.  One 
molecule of putrescine per monomer is present in the expected putrescine binding site.  
A superposition of the F223A/MeAdoMet structure and the wild type structure with 
MeAdoMet shows that there is no appreciable change in the position or conformation 
of the ligand.  The loops disordered in the mutant are also disordered in the wild type 
protein. 
Biochemical Analysis of Potential Inhibitors of hAdoMetDC.  The 
demonstrated importance of the syn conformation of the adenine base of the AdoMet 
substrate for binding in the active site of the enzyme led us to explore whether this 
could be exploited in designing better hAdoMetDC inhibitors.  It is known that 8-
substitution on adenine rings causes the nucleotide to favor a syn conformation in 
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solution (26, 27, 46, 47).  It was thought that structural analogues of AdoMet that 
preferred the syn conformation in solution would lead to improved hAdoMetDC 
inhibition.  Modeling of the active site had indicated that there was sufficient room to 
accommodate even rather large substituents at C8 of adenine.  Several series of 
AdoMet structural analogues were synthesized with substituents ranging from a 
methyl group to a phenyl group at the 8-position of adenine.  Each of these 
compounds was then assayed for their ability to inhibit hAdoMetDC and IC50 values 
for the inhibition were determined (Table 4.3). 
The inhibitors tested fall into four groups as described in the "Chemical 
Synthesis" sub section.  One group (12a-c, 14a-f, 5) has an aminooxyalkyl side chain 
at C-5′, which can form a Schiff base with the pyruvate of AdoMetDC(20, 48-50)  
Compounds of this group were potent inhibitors with a 4-aminooxybutyl group being 
slightly superior to a 2-aminooxyethyl addition.  A second group of compounds 
(17d,e,f,j,k,l,m) had an amide or a hydrazide side chain at C-5′ and a third group of 
inhibitors (18a,b,d,e,f; 19a,b,c,d; 21c,d) had an aminoalkylamino side chain at C-5′.  
Also related to the third group by the synthetic method are 22a and 22c, which, 
respectively, have a guanidine and an amidoxime at the end of the C-5′ side chain.  
The compounds of groups 2 and 3 were less potent (particularly those with the 
aminoalkylamino, guanidine, or amidoxime side chain) but are more likely to be stable 
under in vivo conditions.  The final group of compounds consisted of 5′-
dimethylamino (23a,b) or 5′-dimethylsulfonio (25b,d) compounds.  Compound 25d 
has previously reported to be an AdoMetDC inhibitor with a Ki in the µM range (32).  
As shown in Table 4.3, the replacement of sulfur by nitrogen slightly improves the 
AdoMetDC inhibition. 
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 Table 4.3.  Inhibition of  hAdoMetDCa.   
Compound IC50 
12a 7 nM 
12b 86 nM 
12c < 5% inhibition at 100 µM 
14a 49 nM 
14b < 5% inhibition at 100 µM 
14c 11 nM 
14d 5 nM 
14e 15 nM 
14f 18 nM 
5 (MAOEA) 55 nM 
17d 400 nM 
17e 4 µM 
17f < 5% inhibition at 100 µM 
17j 7 µM 
17k 170 nM 
17l 1.5 µM 
17m 31 µM 
18a 440 µM 
18b < 5% inhibition at 100 µM 
18d 500 µM 
18e < 5% inhibition at 100 µM 
18f 88 µM 
19a < 5% inhibition at 100 µM 
19b < 5% inhibition at 100 µM 
19c < 5% inhibition at 100 µM 
19d < 5% inhibition at 100 µM 
21c 70 µM 
21d 420 µM 
22a < 5% inhibition at 100 µM 
22c 157 µM 
23a 600 nM 
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Table 4.3. (Continued)  
23b 9 µM 
25b 3 µM 
25d 15 µM 
a Each of the potential inhibitors was assayed for the ability to inhibit hAdoMetDC. At 
least five concentrations of each compound were used and IC50 values were calculated 
from curve fits to plots of inhibitor concentration versus % inhibition of hAdoMetDC. 
 
Within each of these groups, there was a consistent improvement of inhibitory 
activity when an 8-methyl substituent was added to the adenine ring.  The reduction in 
the IC50 value varied from 3.4-fold for compound 14d to 15-17-fold for compounds 
23a and 17d.  There was an 8-fold increase in potency when an adenine 8-methyl 
substituent was added to compound 5 (MAOEA) forming compound 12a.  This is 
consistent with the concept that the 8-methyl substitution on adenine biases the 
corresponding nucleoside toward the syn conformation and that this is the form that is 
bound at the active site.  An adenine 8-hydroxy substituent resulted in slightly 
increased potency compared to no substituent, but was not as effective as the 8-methyl 
substituent (compare 14c to 14f and 14d).  Larger 8-substitutions did not improve the 
effectiveness.  An 8-phenyl addition to compounds 5, 14f and 18d abolished the 
inhibitory activity.  Smaller additions such as 8-ethyl (compare 14d and 14e, 17d and 
17e, and 21c and 21d) or 8-methylamino (compare 12a and 12b and 21c and 18a) 
were tolerated but were not as potent as 8-methyl. 
Crystal Structures of hAdoMetDC Complexes.  The crystal structure of native 
hAdoMetDC with 12a was solved using molecular replacement (Figure 4.9 A).  As 
noted above, 12a is structurally similar to the previously studied inhibitor MAOEA 5 
except that it has a methyl substitution at the 8-position on the adenine base.  The 
electron density indicates that the amino terminus of 12a forms a Schiff base with the 
pyruvoyl group of the enzyme.  The adenine base of 12a adopts a syn conformation in 
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the crystal structure as expected.  There is one molecule of putrescine bound in the 
putrescine binding site. 
The crystal structure of native hAdoMetDC with 14e was solved using 
molecular replacement (Figure 4.9 B).  Compound 14e is similar to MAOEA 5 except 
for an ethyl substituent on the 8-position of the adenine base and two extra carbon 
atoms between the tertiary nitrogen (near ribose) and the terminal nitrogen.  The 
presence of a three-carbon linker between the ribose and the amino terminus makes 
this ligand interesting to study.  The electron density maps show no density for Schiff 
base formation between the pyruvoyl group and the amino terminus of the ligand.  
There is no density for the terminal three atoms of the ligand but there is good density 
for the rest of the ligand.  The position of the last three atoms was obtained by 
modeling them to an energetically favorable conformation using molecular modeling.  
The density around the pyruvoyl group fits it well and does not show any evidence of 
formation of a Schiff base.  The ribose makes the critical hydrogen bonds to Glu247 
and anchors the ligand.  The nucleoside is held in the syn conformation and is 
stabilized by π-π stacking.  The density of the ethyl substituent on the base is well 
defined indicating that the substituent is not disordered. 
The crystal structures of hAdoMetDC with 17d (Figure 4.9 C), 17f (Figure 4.9 
D) and 21c (Figure 4.9 E) were also determined by molecular replacement.  The three 
ligands have 8-methyl substituents; the first two have carboxamide end groups at the 
5´-tail, while the third ligand has an amino group in this position.  All three ligands 
showed clear electron density and all three ligands bound in the syn conformation. 
Section 4.3. Discussion 
The active site of AdoMetDC contains a bound pyruvoyl cofactor.  The 
interactions of various ligands at the active site were previously elucidated from the  
 
  107 
 
 
 
 
 
 
 
 
 
Figure 4.9 Complexes of hAdoMetDC with inhibitors having 8-substitutions. The 
carbon atoms of the inhibitor are shown in green and the pyruvoyl group is shown in 
magenta. Water molecules are shown as red spheres and hydrogen bonds are shown as 
dashed lines. (A) Complex with 12a. The ligand makes a Schiff base linkage to the 
active site pyruvoyl group.  (B) Complex with 14e.  There is no evidence from the 
electron density for the formation of a Schiff base and there is no density for the 
terminal three atoms of the ligand.  The position of the terminal three atoms is 
determined by modeling. (C) Complex with 17d. The carboxy terminus of the ligand 
makes hydrogen bonds to Leu65 and Ser229. (D) Complex with 17f. The carboxy 
terminus of the ligand makes water mediated hydrogen bonds to Glu11 and Gly9.  (E) 
Complex with 21c. The amino terminus of the ligand makes water mediated hydrogen 
bonds to Glu11 and Gly9.  The inhibitors 17d, 17f and 21c do not make a Schiff base 
to the enzyme and are hence competitive inhibitors.  The adenine base of all the 
inhibitors attains a syn conformation.
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crystal structures obtained from complexes of the enzyme with the inhibitors MHZPA 
3 (PDB 1I79), MAOEA 5 (PDB 1I72), MeAdoMet (PDB 1I7B), MGBG 1 (PDB 
1I7C), and CGP48664A 2 (PDB 1I7M) (25).  The crystal structure of MeAdoMet 
covalently bound to the enzyme most closely approximates the substrate AdoMet in 
the active site.  The crystal structure shows key interactions of MeAdoMet with the 
enzyme including: (1) hydrogen bonding of the ribose oxygens with Glu247, (2) π-π 
stacking interactions of the adenine ring with Phe223 and Phe7, (3) hydrogen bonding 
of the 6-amino substituent of the adenine ring with the Glu67, the C-terminal residue 
of the β-chain and (4) hydrogen bonding of N-1 of the adenine ring with the backbone 
amide group of Glu67 (Figure 4.7).  Similar interactions are also present in the 
structures of MHZPA 3 and MAOEA 5 complexed with hAdoMetDC.  The glycosidic 
angle for the adenine base in the structures ranges from 128° to 139°, which 
demonstrates a preference for the syn conformation of the nucleoside when bound to 
the active site. Crystal structures of MGBG 1 and CGP48664A 2 with the enzyme 
show that they stack between the two phenyl rings and make hydrogen bonds to 
Glu247. 
The molecular modeling of MeAdoMet in the active site of hAdoMetDC was 
performed by using mixed Monte Carlo/Low Mode conformational searching as 
described above.  The glycosidic torsional angle was free to rotate during the 
conformational search, which would allow a wide range of  rotomers that are 
compatible with the steric constraints of the active site before energy minimization.  
The low energy structures show that the adenine-derived nucleosides prefer the syn 
conformation in the active site of hAdoMetDC.  Markham et al.  have studied the 
conformational preferences of AdoMet in solution and in vacuo (44).  These studies 
based on 1H NMR and calculations based on NMR constraints have showed that 
AdoMet prefers an anti conformation in solution and a syn conformation in vacuo.  In 
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solution, the energy difference between the anti and the corresponding syn 
conformation, which includes steric, electrostatic and the solvation contributions, is 
around -34 kJ/mol.  However, these calculations were based on molecular mechanics 
without polarization effects and it is likely that the energy difference is much less 
negative.  Our crystal structures and modeling results show that hAdoMetDC binds 
ligands in the syn conformation and that the energy difference is overcome by 
hydrogen bonding and π-π interactions Phe7 and Phe233.  Typical π-π interactions of 
parallel geometry account for a stabilization of 8-12 kJ/mol (51), suggesting that other 
factors may be involved. 
The roles of Phe223 and Phe7 in AdoMetDC were previously studied through 
crystal structures and kinetic experiments (25).  Kinetic data from reaction of 
hAdoMetDC F223A and Phe7A mutants with the substrate AdoMet have shown that 
there is a 45-fold reduction of efficiency (kcat/km) for the F7A mutant and a 1400-fold 
decrease with the F223A mutant.  In addition, MGBG 1 and CGP48664A 2 show a 
significant increase in the IC50 values for both the F7A and F233A mutants when 
compared to the wild-type enzyme, with decrease in binding greater for the F223A 
than for F7A. Therefore, we chose to investigate the structural and conformational 
properties of MeAdoMet in the active site of the F223A mutant. 
Our conformational searches with virtual mutations were done to understand 
the roles of Phe223 and Phe7 in stabilizing the syn conformation.  In contrast to 
calculations done with the wild type enzyme structure, in which only the syn 
conformation was observed for the ensemble of lowest energy structures, the global 
minimum from both the mutations has the base in an anti conformation and the next 
higher energy structure has the base in a syn conformation.  The difference in the 
energy between these conformations is about 2 kJ/mol, which we estimate to be within 
the error limit of our molecular mechanics based calculations.  The energy difference 
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between the syn and anti conformation of both structures is low, and based on the X-
ray structure of hAdoMetDC F223A with bound MeAdoMet, the enzyme binds the 
ligands in the syn conformation, suggesting that π-π interactions with Phe7 are 
sufficient to maintain the syn conformation.  Thus, although the modeling studies were 
incapable of accurately predicting that the syn conformation of the nucleoside would 
be maintained in the F223A mutant, it was possible to infer from these studies that the 
binding affinity of the nucleoside for the enzyme would be diminished.  
Our attempts to exploit the requirement by AdoMetDC for a ligand with a syn 
conformation were successful as demonstrated by the 8 to 18-fold improvement in 
inhibition when a methyl group is attached to C-8.  However, the larger substituents 
that we tested provided no benefit over the unsubstituted parent compounds.  In fact, 
the 8-phenyl substituent rendered the compounds much less potent than the 
unsubstituted analogue.  Modeling studies of the active site had indicated that there 
should be sufficient space to accommodate the larger groups with the adenine in the 
syn conformation.  A more detailed look at the area occupied by adenine C-8 
substituents has indicated that this area is near the solvent interface.  Based on our 
biochemical results, although large 8-substituents were structurally compatible with 
the active site, the penalty of incompletely burying a large hydrophobic group within a 
hydrophobic cavity is apparently greater than the gain from favoring the syn 
conformation.  We are now exploring the effect of more hydrophilic C-8 adenine 
substituents that should be more compatible with proximity to the solvent.  Such 
substituents may be useful in maintaining the inhibitory potency associated with the 
syn structure while still allowing species specific binding. 
Structures of many of the AdoMet analogues bound to AdoMetDC have shown 
that they inhibit the enzyme through Schiff base formation with the pyruvoyl group of 
the enzyme.  The linker length between the tertiary ammonium/sulfur and the terminal 
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nitrogen of those inhibitors is typically 3-4 atoms, which makes the formation of a 
Schiff base geometrically and sterically feasible. Compound 14e has a linker length of 
five atoms.  The electron density map for the complex of 14e shows a break in the 
density after the pyruvoyl group, suggesting that there is no Schiff base formation.  
There is good density for the ligand except at the three terminal atoms, which are 
disordered and have no density.  The positions of the last three atoms were fixed in an 
energetically favorable conformation using computer modeling.  The five atoms of the 
linker region appear to cause a sterically unfavorable orientation for formation of the 
Schiff base.  The ligand is still held rigidly in the active site by hydrogen bonds to 
Glu247 and the π-π stacking interactions with Phe7 and Phe223 and thus little 
movement is allowed to accommodate Schiff base formation for the longer linker 
region.  Even though compound 14e is not covalently attached to the pyruvoyl group 
its potency is better than MAOEA 5 and nearly as good as compound 12a. 
Conclusion. Previous structural studies showed that AdoMet binds to the 
active site of hAdoMetDC in the syn conformation, suggesting that adenosine 
analogues favoring the syn conformation in solution might be more potent inhibitors 
than corresponding analogues favoring the lower energy anti conformation.  8-
Substituted nucleoside analogues favor the syn conformation because of unfavorable 
interactions in the anti conformation between a bulky 8-substituent and ribose.  We 
used computer simulations to predict 8-substituted compounds that might bind to 
hAdoMetDC, and synthesized and assayed the most promising candidates.  We also 
determined crystal structures of several compounds bound to hAdoMetDC to validate 
the predictions; the structures confirmed that the 8-substituted analogues bound in the 
syn conformation and retained the previously identified features of AdoMet binding, 
namely, purine stacking between Phe7 and Phe223, and hydrogen bonding between 
the ribose hydroxyl groups and Glu247.  A group of adenosine analogues was 
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generated by varying the size and nature of the both the 8-substitutent and the 5'-
modification.  In general, 8-substituted analogues bound with a potency of 8 to 18-fold 
higher compared to the corresponding compound with a hydrogen atom at the 8-
position; however, 8-substituents larger then methyl often showed lower potency than 
the corresponding 8-H compound.  The observation results from excessive solvent 
exposure for large 8-substituents.  Computer modeling and X-ray crystallography were 
also used to understand the preference for the syn conformation.  Modeling studies 
suggested an important role for the two active site phenylalanine residues in addition 
to Glu247; however, the crystal structure of the F223A mutant hAdoMetDC showed 
that AdoMet still binds in the syn conformation, suggesting that other factors that 
favor the syn conformation remain to be identified. 
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CHAPTER 5 
COMPLEXES OF THERMOTOGA MARITIMA S-ADENOSYLMETHIONINE 
DECARBOXYLASE WITH SUBSTRATE ANALOGS PROVIDE INSIGHTS INTO 
SUBSTRATE SPECIFICTY AND INHIBITOR DESIGN 
Section 5.1. Introduction 
S-Adenosylmethionine decarboxylase (AdoMetDC) is a critical enzyme at a 
key branch point in the polyamine biosynthetic pathway (1-4).  AdoMetDC catalyzes 
the decarboxylation of S-adenosylmethionine (AdoMet) to S-adenosyl-5´-(3-
methylthiopropylamine) (dcAdoMet).  The propylamine group from dcAdoMet is 
transferred to putrescine and spermidine to form spermidine and spermine 
respectively.  The primary role of AdoMet in cells is as a methyl group donor to a 
variety of substrates.  After the decarboxylation process, dcAdoMet is committed to 
polyamine biosynthesis.  The polyamines putrescine, spermidine and spermine are 
ubiquitous across all forms of life and are implicated in cellular growth and 
differentiation.  Elevated levels of polyamines are associated with various tumors and 
parasitic diseases (5, 6).  AdoMetDC and other enzymes in the polyamine biosynthetic 
pathway are promising targets for anti-tumor and anti-proliferative diseases (7, 8). 
AdoMetDC is expressed as a proenzyme and undergoes an internal serinolysis 
reaction as part of a post-translational modification to generate the active site pyruvoyl 
group.  This process cleaves the peptide chain to α and β chains with the pyruvoyl 
group generated at the N-terminus of the α chain.  The α chain is derived from the 
carboxy end of the proenzyme and the β chain is derived from the amino end of the 
proenzyme.  The crystal structures of wild type human AdoMetDC (hAdoMetDC) and 
the H243A and S68A mutants provided insights into the mechanism of auto-
processing of the enzyme (9-11).  The crystal structures of AdoMetDC from plants 
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and Thermotoga maritima have also been determined (12, 13).  The dimeric fold of T. 
maritima AdoMetDC (TmAdoMetDC) is similar to the monomeric protomer of 
human and plant AdoMetDC, suggesting evolutionary links of gene duplication and 
fusion.   
The crystal structure of the human enzyme has been determined complexed to 
various ligands and substrate analogs (14).  The complex of the human enzyme with S-
adenosylmethionine methyl ester (MeAdoMet) reveals key interactions of the ligand 
with the active site residues and the binding conformation of the ligand.  The ligand 
makes a Schiff base with the pyruvoyl group and the adenine base binds in an unusual 
syn conformation stabilized by stacking interactions with Phe223 and Phe7 and 
hydrogen bonds to Glu67.  The hydroxyl groups of the ribose make two hydrogen 
bonds to Glu247.  No information is available in terms of the substrate/ligand binding 
conformation for prokaryotic AdoMetDCs.  The crystal structures of the proenzyme 
and the non-processible S63A mutant of TmAdoMetDC have been reported 
previously (13).  In this paper, we report the crystal structure of processed 
TmAdoMetDC and the complexes with MeAdoMet and 5´-deoxy-5´-dimethyl 
thioadenosine (MMTA).  We compare the complexes from T. maritima with the 
complexes from hAdoMetDC.  The comparison and the conservation of the active site 
residues reveal recurring themes for substrate recognition and inhibitor design  
Section 5.2. Materials and Methods 
Protein expression, processing and purification.  The expression and 
purification protocol of TmAdoMetDC is described in a previous paper(13).  The 
pTmSpeD.28 plasmid encoding the enzyme was transformed into the B834(DE3) 
strain of E. coli.  An overnight starter culture of 10 mL was grown in LB media 
supplemented with 35 µg/mL kanomycin. It was then introduced into a 1 L cell culture 
and grown until the O.D600 reached 0.6 and subsequently induced with 1 mM 
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isopropyl β-D-thiogalactoside.  The temperature was reduced to 15 °C and the protein 
expressed overnight.  The cells were harvested by centrifugation and stored at –80 °C.  
The cells were suspended in a wash buffer consisting of 50 mM Tris-HCl, pH 
8.0, 10 mM imidazole, and 500 mM NaCl and lysed using a sonicator.  Processing of 
the enzyme was induced by heating the lysate at 80 °C for 1 h.  The heating process 
also served as a partial purification step.  The lysate was centrifuged and the 
supernatant was passed through a Ni-NTA column equilibrated with the wash buffer.  
The column was washed with 100 mL wash buffer followed by 50 mL of buffer 
containing 50 mM Tris-HCl, pH 8.0, 35 mM imidazole, and 500 mM NaCl.  The 
protein was eluted with elution buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM 
imidazole, and 500 mM NaCl, and dialyzed into 20 mM Tris-HCl, pH 8.0, and 1 mM 
dithiothreitol.  The protein was concentrated to 6 mg/mL and stored at –80 °C. 
Crystallization conditions.  The protein was crystallized using the hanging 
drop vapor diffusion method at room temperature.  The crystallization conditions were 
2.4 – 2.8 M ammonium formate, and 100 mM HEPES, pH 8.0.  Crystals appeared in 2 
weeks and grew to a maximum size of 0.2 × 0.15 × 0.1 mm in 3-4 weeks.  For the 
crystals of the complexes, the crystals were transferred into a well solution containing 
5 mM MeAdoMet or MMTA, respectively, for 4 h to allow the ligands to soak into the 
active site of the enzyme. 
Data collection and processing.  The data for the processed enzyme was 
collected at our home source on a Rigaku R-AXIS IV++ detector with Cu Kα radiation 
from a Rigaku RU-300 rotating anode generator.  Data were collected over 100° with 
a 0.5° oscillation range and 15 min exposure per frame at a crystal to detector distance 
of 180 mm.  Crystals of the complexes were sequentially transferred into well solution 
containing 5%, 10%, 15% and 20% glycerol and 200 mM concentrations of 
ammonium formate prior to freezing in liquid nitrogen.  The data for the complexes 
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were collected at the 24-ID-E beamline at the NE-CAT sector of the Advanced Photon 
Source.  Data were collected over 140° and 150° for the MeAdoMet and MMTA 
complexes, respectively, with a 1° oscillation range and 1 s exposure per frame at a 
crystal to detector distance of 260 mm.  The data were indexed, integrated and scaled 
using the HKL2000 program suite (15).  The data collection statistics are summarized 
in Table 5.1. 
Structure determination and Refinement.  The structures of the processed 
enzyme and the complexes were solved by molecular replacement using the CNS 
program suite (16).  The structure of the wild type proenzyme (PDB code 1TLU) was 
used as the search model for molecular replacement.  The model building for the 
protein was done by the program COOT (17).  The refinement process included 
successive rounds of simulated annealing, B factor refinement, minimization and 
calculation of composite omit maps and difference Fourier maps. Model building was 
done against the composite omit maps. After several rounds of refinement and model 
building, the difference Fourier and composite omit maps were used to identify 
missing ligands and water molecules.  The topology and parameter files for 
MeAdoMet and MMTA were obtained from the HIC-UP server (18).  The ligand and 
water molecules were added to the structure followed by a few rounds of refinement 
as mentioned above.  The final refinement statistics are shown in Table 5.2. 
Figure preparation.  Figures were prepared using PyMOL (22) and 
ChemDraw.  
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Table 5.1. Summary of Data Collection and Processing Statistics 
 TmAdoMetDC 
Processed 
TmAdoMetDC + 
MeAdoMet 
TmAdoMetDC + 
MMTA 
Wavelength 
(Å) 
1.5418 0.9792 0.9792 
Space group R3 R3 R3 
a = b (Å) 104.71 105.20 105.47 
c (Å) 69.84 70.06 70.11 
Resolution (Å) 2.06 1.90 1.90 
Total 
reflections 
49357 91891 101615 
Unique 
reflections 
16833 22459 22388 
Redundancya 2.9 (1.7) 4.1 (2.3) 4.5 (2.8) 
Completeness 
(%) 
95.4 (71.2) 98.9 (90.4) 97.6 (79.6) 
I/σ 23.1 (4.1) 17.9 (3.1) 24.4 (2.9) 
Rsymb 4.5 (21.0) 9.6 (21.6) 6.5 (23.6) 
Matthews no. 2.49 2.52 2.54 
Solvent content 
(%) 
49.7 50.3 50.8 
 
aValues for the highest resolution shell are given in parentheses. 
bRsym=ΣΣiIi - <I> | /Σ<I>, where <I> is the mean intensity of the N reflections with 
intensities Ii  and common indices h,k,l. 
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Table 5.2. Refinement statistics for processed TmAdoMetDC and complexes 
 TmAdoMetDC 
Processed 
TmAdoMetDC 
+ MeAdoMet 
TmAdoMetDC 
+ MMTA 
Resolution (Å) 2.06 1.90 1.90 
R factora(%) 0.233 0.212 24.9 
Rfreeb (%) 0.262 0.238 28.0 
No of non-H atoms    
 Protein 1868 1917 1900 
 Ligand - 56 42 
 Water 115 108 61 
B factors (Å2)    
 Protein  28.3 33.5 31.0 
 Ligand (Å2) - 54.6/44.4 46.1/41.9 
Rms deviations    
 Bonds (Å) 0.011 0.031 0.006 
 Angles (º) 1.4 1.5 1.2 
 Dihedrals (º) 25.0 27.2 25.3 
Ramachandran plot    
 Most favored 
region (%) 
94.5 95.6 95.6 
 Additional allowed 
region (%) 
5.5 4.4 4.4 
 Disallowed region 
(%) 
0.0 0.0 0.0 
 
aR factor = Σhkl||Fobs|-k|Fcal|/Σhkl|Fobs|, where Fobs and Fcal are observed and calculated 
structure factors respectively.  
bFor Rfree, the sum is extended over a subset of reflections (5% for processed; 10% for 
TmAdoMetDC/MeAdoMet and TmAdoMetDC/MMTA) excluded from all stages of 
refinement. 
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Section 5.3. Results 
Overall structure of processed enzyme.  Heating TmAdoMetDC in crude lysate 
of E. coli induces processing of the enzyme.  The structure of the processed enzyme 
was solved by molecular replacement using the structure of the proenzyme as the 
search model.  The overall structure of processed enzyme in the asymmetric unit is a 
dimer comprised of two 2-fold related protomers. The protomer is a two-layer αβ 
sandwich with an anti-parallel β-sheet flanked by two α-helices (similar to the 
monomer of the proenzyme).  The dimer interface is formed by the interaction of the 
β-sheets of the protomers.  The autoprocessing occurs between residues Glu62-Ser63 
located in a β-turn between residues Val59-His64.  The electron density maps show a 
break in the main chain density and the formation of a pyruvoyl group at Ser63.  
Residues Ser61 and Glu62 are disordered in the processed enzyme and become 
ordered upon ligand binding (see next section).  The active site is at the dimeric 
interface and contains residues from both protomers.  A comparison of the processed 
structure and the proenzyme shows no significant change in the overall secondary 
structure. The overall structure of the processed enzyme is shown in Fig. 5.1 (A).  A 
stereoview of the comparison of the proenzyme and the processed enzyme at the 
processing site is shown in Fig. 5.1 (B). 
Complex with MeAdoMet.  The crystal structure of TmAdoMetDC complexed 
to MeAdoMet was solved by molecular replacement.  The difference Fo- Fc density 
shows that MeAdoMet binds to the enzyme by making a Schiff base with the active 
site pyruvoyl group in both protomers.  The 2´ and 3´ oxygen atoms of the ribose 
make hydrogen bonds to the carboxylate group of Glu72´ (´ marks residues from the 
two-fold related protomer).  The adenine base of MeAdoMet binds in the unusual syn 
conformation stacking against Phe49´.  Residue Phe49´ undergoes a torsional change 
in N-CA-CB-CG angle by 90° to stack against the adenine base.  Residue His47´  
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Figure 5.1. (A) Overall structure of processed TmAdoMetDC.  The dimeric structure 
of the enzyme is shown with the monomers colored green and violet.  The pryuvoyl 
group formed is shown in ball-and-stick and labeled.  (B) Stereoview of the 
superposition of processed enzyme (carbon atoms colored green) and the proenzyme 
(shown in black).  Residues Ser61 and Glu62 are disordered in the processed enzyme. 
 
undergoes a torsional change in N-CA-CB-CG angle by 130° to stack edge-to-face 
against Phe49´.  Residues Ser61 and Glu62 become ordered upon binding of 
MeAdoMet.  The N6 and N1 atoms of the adenine base make two hydrogen bonds to 
the carboxylate and amide group of Glu62, respectively.  The sulfonium ion of 
MeAdoMet is sandwiched between the aromatic rings of Phe49´ and Trp70´.  The 
sulfonium atom is 4.4 Å from the CZ2 atom of the tryptophan ring, which is also the 
closest contact of the sulfonium with Trp70´.  The sulfonium atom is 4.7 Å away from 
the center of the six membered ring of tryptophan.  The sulfonium is 4.2 Å from the 
center of the Phe49´ ring and 3.8 Å from the CD2 and CE2 atoms of the ring, which is 
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also the closest contact of the sulfonium with Phe49´.  Residue Tyr52´ undergoes a 
torsional change in the N-CA-CB-CG angle by 100°, moving closer into the active site 
upon ligand binding.  Tyr52´ partially shields MeAdoMet from the external solvent.  
A stereoview of MeAdoMet bound to TmAdoMetDC is shown in Fig. 5.2 (A). A 
schematic view of the interactions of MeAdoMet with the active site residues is shown 
in Fig. 5.3. 
Complex with MMTA.  The crystal structure of TmAdoMetDC complexed to 
MMTA was solved by molecular replacement.  MMTA lacks the terminal nitrogen 
group necessary to make a Schiff base to the enzyme and binds as a competitive 
inhibitor.  The difference Fo- Fc maps show MMTA binding in the active site in both 
protomers.  The enzyme undergoes conformational changes in residues Phe49´, His47´ 
and Tyr52´ (as explained in the previous section) upon MMTA binding.  The adenine 
base of MMTA binds in the syn conformation stacking against Phe49´.  The 2´ and 3´ 
oxygen atoms of the ribose make hydrogen bonds to the carboxylate group of Glu72´.  
The N1 atom of the adenine base makes a hydrogen bond to the amide group of 
Glu62. The carboxylate end of Glu62 is disordered in chain D and attains an alternate 
conformation in chain B.  The density for the terminal end of Glu62 is too weak to 
assign a second hydrogen bond between the N6 atom of the adenine base and the 
carboxylate end of Glu62 as seen in the MeAdoMet complex.  The sulfonium atom is 
4.3 Å from the CZ2 atom of the tryptophan ring, which is also the closest contact of 
the sulfonium with Trp70´.  The sulfonium atom is 4.5 Å away from the center of the 
six membered ring of tryptophan. The methyl group on the sulfonium is partially 
positive charged and is 4.1 Å from the center of the Trp70´ ring and 3.6 Å from the  
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Figure 5.2. Complexes of TmAdoMetDC. (A) Stereoview of MeAdoMet covalently 
bound to the enzyme.  The pyruvoyl group has carbon atoms colored pink and 
MeAdoMet has carbon atoms colored green.  (B) Stereoview of MMTA bound to the 
enzyme.  The pyruvoyl group has carbon atoms colored brown and MMTA has carbon 
atoms colored green.  Hydrogen bonds are shown as dashed lines. 
 
CZ2 atom of the ring, which is also the closest contact of the methyl group with 
Trp70´.  The sulfonium is 4.5 Å from the center of the Phe49´ ring and 4.0 Å from the 
CD2 and CE2 atoms of the ring, which is also the closest contact of the sulfonium 
with Phe49´.  A stereoview of MMTA bound to TmAdoMetDC is shown in Fig. 5.2 
(B).  
Section 5.4. Discussion 
Processing of AdoMetDC.  AdoMetDC is ubiquitously expressed as a 
proenzyme and undergoes internal serinolysis to mature to the active enzyme.  The 
self-processing occurs between a glutamate and serine residue resulting in the 
formation of a pyruvoyl group from the serine residue.  Processing occurs  
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Figure 5.3. Schematic view of interactions of MeAdoMet in the active site of 
TmAdoMetDC. 
spontaneously in the human and the potato enzyme as seen in the crystal structures 
and supported by the activity studies (9, 10, 12).  Putrescine activates the processing 
and decarboxylation rates of hAdoMetDC (10, 23).  Mechanical strain in the β-turn 
preceding the cleavage site has been implicated in autoprocessing in histidine 
decarboxylase and aspartate decarboxylase (24, 25).  The processing site in 
TmAdoMetDC is in a β-turn and processing was induced by heating the enzyme for 1 
h at 80 °C.  The heat treatment for processing might be a physiologically relevant step 
as T. maritima is a thermophilic bacteria with an optimum growth at 80 °C.  
Comparison of the processed enzyme and the proenzyme reveals no significant 
changes in the secondary structure, suggesting that mechanical strain might not play a 
role in processing of the enzyme.  
The mechanism of processing of hAdoMetDC has been extensively studied 
through site directed mutagenesis and crystal structures as reported previously (10, 11, 
13).  The conservation of active site residues in TmAdoMetDC suggests that the 
mechanism of processing is similar.  The hydroxyl group of Ser63 attacks the carbonyl 
atom of the adjacent Glu62 resulting in the formation of an oxyoxazolidine 
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intermediate.  The hydroxyl group needs to be activated for such an attack and there is 
no basic residue in the vicinity for such a role.  The activation of Ser63 could occur by 
a water molecule, but there is no clear evidence for the activation process.  The 
oxyoxazolidine intermediate collapses to generate the ester intermediate.  The amide 
hydrogen of Ser63 is abstracted by His68´ resulting in the cleavage of the protein 
backbone to the α and β chains.  The dehydroalanine residue at the N-terminus of the 
α chain undergoes tautomerization and subsequent hydrolysis to generate the pyruvoyl 
group. 
Substrate specificity of AdoMetDC.  Biochemical studies have shown that 
substrate analogs lacking a positive charge do not bind to hAdoMetDC (26, 27).  The 
crystal structure of hAdoMetDC has been determined with various ligands that are 
substrate analogs (14).  Substrate analogs lacking positive charge at the sulfonium 
position do not bind to the enzyme as analyzed from the crystal structures (data not 
shown).  The crystal structures of the enzyme with various ligands reveal that the 
positive center stacks between Phe223 and Phe7 and the substrate specificity arises 
from the favorable cation-π interactions between the sulfonium and the aromatic rings. 
The complexes of TmAdoMetDC with MeAdoMet and MMTA reveal similar 
interactions to those seen in the human enzyme.  The sulfonium center of MeAdoMet 
and MMTA is sandwiched between Trp70´ and Phe49´.  The geometry and distance of 
the sulfonium center from the aromatic rings are favorable for a cation-π interaction.  
Cation-π interactions in biology are implicated in protein stability, ligand recognition, 
catalysis and ion channels (28, 29 , 30).  The strength of the interaction depends on the 
distance and geometry of the cation from the aromatic ring and also on the nature of 
the cation and the interacting aromatic group. There are no negative charged residues 
around the sulfonium center in either enzyme and the critical necessity of the positive 
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charge for binding suggests that the cation-π interaction plays a significant role in 
ligand recognition in AdoMetDC. 
Ligands binding to AdoMetDC.  The adenine base of the ligand binds in an 
unusual syn conformation in hAdoMetDC.  The base is sandwiched between Phe223 
and Phe7 for favorable π stacking interactions.  The N6 and N1 atoms of the adenine 
base make two hydrogen bonds to the carboxylate and amide group of terminus of 
Glu67, respectively.  The syn conformation is further stabilized by electrostatic 
interactions between the N3 atom of the base and the sulfonium center (unpublished 
data).  The crystal structure of the F223A mutant with MeAdoMet shows that the 
adenine base still binds in the syn conformation, suggesting that π stacking to Phe7, 
hydrogen bonding to Glu67 and electrostatic effects are sufficient to stabilize the 
adenine base in the higher energy conformation (31). 
Both of the ligands MeAdoMet and MMTA bind to TmAdoMetDC in the high 
energy syn conformation.  The syn conformation is stabilized by π-π interactions with 
Phe49´.  The adenine base is positioned edge-to-face 5.4 Å away from Trp70´ (residue 
identical to Phe7 in hAdoMetDC) and does not have a favorable geometry or distance 
for stabilization by the aromatic ring.  In the syn conformation, the N3 atom of the 
adenine base is partially negatively charged and is present 3.7 Å away from the 
positive charge of the sulfonium center in the MeAdoMet complex.  In the MMTA 
complex, the distance between the corresponding atoms is 3.4 Å. Electrostatic 
interactions and hydrogen bonding to Glu62 further stabilize the syn conformation of 
the adenine base. 
Comparison of T.maritima and Human AdoMetDC.  The crystal structure of 
the processed form of TmAdoMetDC provides the first insight into the active form of 
the enzyme from prokaryotes.  The similarity in the overall structure of 
TmAdoMetDC and hAdoMetDC also presents a strong case of protein evolution as 
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discussed previously.  TbAdoMetDC is a homodimer formed by two protomers related 
by 2-fold symmetry.  Processing is observed in both the protomers are the active sites 
in the dimer are separated by ~26 Å.  The human enzyme is a homodimer comprising 
of two (αβ) protomers.  The N-terminal and C-terminal halves of hAdoMetDC are 
structurally homologous to each other and also to the protomer of TbAdoMetDC 
suggesting that the human enzyme evolved by gene duplication and subsequent fusing.  
The superposition of the processed from of TbAdometDC and hAdoMetDC is shown 
in Figure 5.4.  The human enzyme has two extra β strands extending out the central β 
sheet in both the N-terminal and C-terminal half when compared to TbAdoMetDC. 
The complexes of TmAdoMetDC with MeAdoMet and MMTA further 
elucidate the role of the active site residues in binding the substrate as well as the 
autoprocessing and decarboxylation reactions.  The comparison of the active site 
reveals the absolute conservation of the residues involved in the autoprocessing and 
decarboxylation processes of both the enzymes (shown in Table 5.3).  The only outlier 
of the absolute conservation is Trp70´ that is mutated to a phenylalanine in the human 
enzyme.  The mutation from tryptophan to phenylalanine would conserve the role of 
the amino acid residue in stacking the adenine base of the substrate.  The processing 
site in the C-terminal half of the enzyme is lost due to the mutation of Glu-Ser 
(essential motif for processing) to Gly-Thr, mutation of residues essential for substrate 
binding/decarboxylation and an insertion of an amino acid in the β turn Lys234-
Thr238 (comparison of residues shown in Table 5.4). 
As discussed in the previous sections, cation - π interactions determine the 
substrate specificity in both the AdoMetDCs and the enzymes would bind the 
substrate AdoMet in the syn conformation.  The role of AdoMet in cells is 
predominantly a methyl group donor.  The process would be facilitated if AdoMet is 
in the more open anti conformation.  For the decarboxylation process, the substrate  
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Figure 5.4. Superposition of processed form of TbAdoMetDC (blue) and hAdoMetDC 
(orange).  The pyruvoyl cofactor is shown as sticks. 
 
 
Table 5.3. Active site residues in TmAdoMetDC and hAdoMetDC 
 
T. maritimaa Human Role 
Pyr63 Pyr68 Schiff base to the substrate 
His68´ His243 Base for autoprocessing 
Phe49´ Phe223 Stacking adenine base & sulphonium 
of substrate 
Trp70´ Phe7 Stacking adenine base & sulphonium 
of substrate 
Glu72´ Glu247 Hydrogen bonding to ribose moiety of 
substrate 
Cys83 Cys82 Acid for decarboxylation 
Glu62 Glu67 Hydrogen bonding to adenine base of 
substrate 
Ser55´ Ser229 Positioning base for autoprocessing 
 
a Residues labelled (´) come from the two-fold related protomer  
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assumes the unusual, closed syn conformation which is stabilized by residues 
conserved in prokaryotes and higher organisms. 
Implications for drug design.  Regulating the polyamine biosynthetic pathway 
and maintaining polyamine levels is a promising therapeutic strategy for cancer and 
parasitic diseases.  Inhibitors of AdoMetDC have potential application as anti-cancer 
agents and have been a subject of clinical trials (32, 33).  The development of 
substrate analogs such as MHZPA and MAOEA as inhibitors resulted in compounds 
that inhibit human AdoMetDC with IC50 values in the nM to pM range (unpublished 
data).  The key interactions of the inhibitors with the active site of the enzyme include: 
(a) hydrogen bonding to Glu247 and Glu67, (b) stacking interactions with Phe7 and 
Phe223, (c) cation-π interactions to Phe223, and Phe7 (d) interactions with the 
pyruvoyl group.  The complexes of TmAdoMetDC reveal the conservation of key 
interactions mentioned above in prokaryotes when compared to higher organisms 
(Figure 5.5).  
The inhibitors of polyamine biosynthesis have potential applications in the 
treatment of African trypanosomiasis and other parasitic infections.  The crystal 
structure of AdoMetDC from T. brucei (TbAdoMetDC) has not been determined.  The 
structure of TbAdoMedDC would provide a template for structure-based drug design 
for AdoMetDCs relevant to parasitic infections.  It has been recently discovered that 
TbAdoMetDC exists as a heterodimeric complex formed by the active enzyme and a 
catalytically inactive homolog termed the prozyme (34). The sequence alignment 
between human and TbAdoMetDC shows that residues Glu266, Tyr242, Phe28 and 
Glu85 in TbAdoMetDC are likely to be involved in substrate binding.  Residues 
Glu266 and Glu85 are equivalent to Glu247 and Glu67, and residues Tyr242 and 
Phe28 are equivalent to Phe223 and Phe7 in the human enzyme, respectively.  The 
conservation of the nature of the substrate binding residues suggests that the parasitic 
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Figure 5.5. Stereoview of the comparison of active sites of TmAdoMetDC (carbon 
atoms colored green) and human AdoMetDC (carbon atoms colored cyan) with 
MeAdoMet bound.  Hydrogen bonds are omitted for clarity.  
 
Table 5.4. Comparison of residues in the second “active” sitea 
T. maritima Human Role 
Ser63 Thr238 Pyruvoyl froming residue 
Glu62 Gly237 Residue in the β turn 
Ser61 Asp236 Residue in the β turn 
- Ser235 Residue in the β turn 
Ile60 Lys234 Residue in the β turn 
Val59 Met233 Residue in the β turn 
His68 Ser73/Arg76 Base for processing 
Ser55 Gln60 Base for processing 
Cys83 - Acid for decarboxylation 
aSer73 and Arg76 are positioned in a similar position to His68.  Missing residues in 
equivalent positions in the human enzyme are indicated by a dash. 
AdoMetDC binds ligands in a similar fashion to the human and the prokaryotic 
enzymes.  The similarity also suggests that inhibitors designed for hAdoMetDC have a 
potential to block activity of AdoMetDCs in other species 
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CHAPTER 6 
CONCLUSIONS 
 Structure based drug design employing X-ray crystallography as a tool is 
gaining wider acceptance by pharmaceutical companies and academia in reducing the 
costs associated with drug discovery and reduce the time frame involved for drug 
development.  S-Adenosylmethionine decarboxylase (AdoMetDC) is an attractive 
target for inhibitor design in the polyamine biosynthetic pathway.  The enzyme is 
expressed as an inactive proenzyme which undergoes internal serinolysis as a post-
translational modification to mature into the active form.  In humans, the rate of the 
autoprocessing and decarboxylation reactions are activated by putrescine which binds 
at the allosteric site in the enzyme.  Biochemical assays indicate that a positive charge 
at the position of the sulphonium of the substrate is essential for substrate analogs to 
inhibit AdoMetDC.  Previously obtained crystal structures showed that AdoMetDC 
binds substrate analogs in the unusual and higher energy syn conformation.  The 
existence of a proenzyme, activation by putrescine, requirement of positive charge for 
inhibition and the binding of ligands in the syn conformation make AdoMetDC an 
interesting target to pursue for inhibitor design. 
The tools of structure based drug discovery were used in understanding the 
molecular details of inhibition of human AdoMetDC at various sites and stages of the 
enzyme lifetime.  The activity of AdoMetDC can be blocked by (1) Inhibiting the 
putrescine binding site (2) Inhibiting the active site (3) Inhibiting the autoprocessing 
reaction.  The crystal structures of human AdoMetDC solved previously identified the 
putrescine binding site and the interactions putrescine would make with the enzyme.  
To investigate the structural basis of putrescine activation, the crystal structure of the 
wild type AdoMetDC, D174N, E178Q, and E256Q mutants in the putrescine free form 
were obtained.  The comparison of the crystal structures revealed that putrescine 
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effects are primarily electrostatic that orient the catalytic residues through a hydrogen 
bonding network mediated by Lys80. 
The crystal structure of AdoMetDC with substrate analogs 5´-deoxy-5´-[N-
methyl-N-(3-hydrazinopropyl)amino]adenosine (MHZPA), 5´-deoxy-5´-[N-methyl-N-
[(2-aminooxy)ethyl]amino]adenosine (MAOEA), and the methyl ester of S-
adenosylmethionine (MeAdoMet) elucidated the interactions of potential inhibitors 
with the active site of the enzyme.  The structural information obtained from these 
complexes was used to rationally design inhibitors to the active site of the enzyme.  
The inhibitors synthesized broadly fall into four categories based on the terminal 
group at the 5´ end of the ribose moiety.  The crystal structure of human AdoMetDC 
was obtained cocrystallized with a representative ligand from each of the category of 
ligands synthesized. 
The complexes of AdoMetDC with competitive inhibitors 5´-deoxy-5´-
(dimethylsulfonio)adenosine (MMTA) and 5´-deoxy-5´-(N-dimethyl)amino-8-
methyladenosine (DMAMA) were obtained.  The structural information from the 
complexes combined with quantum chemical calculations and stopped flow 
experiments provided insights into ligand specificity of AdoMetDC.  The positive 
charge on the central sulphur/nitrogen atom of the ligands stacks between Phe223 and 
Phe7 and is stabilized by favorable cation - π interactions to the aromatic rings.  The 
stabilization obtained by cation - π interactions is ~ 4.5 kcal/mol as obtained from 
quantum chemical calculations.  The stopped flow experiments demonstrate that the 
importance of residues in binding ligands follows the order Phe223 ~ Glu247 >> 
Phe7.  
The crystal structure of the F223A mutant of AdoMetDC complexed to 
MeAdoMet revealed that the ligand binds to the enzyme in the syn conformation.  The 
crystal structure of human AdoMetDC was obtained complexed with 5´-deoxy-5´-[(3-
  145 
aminopropyl)methylamino]-8-methyl-adenosine, 5´-deoxy-5´-[(2-
carboxamidoethyl)methylamino]-8-methyl-adenosine, 5´-deoxy-5´-[(2-
aminooxyethyl)methylamino]-8-methyl-adenosine, 5´-deoxy-5´-[(4-
aminooxybutyl)methylamino]-8-ethyl-adenosine, and 5´-deoxy-5´-
[(carboxamidomethyl)methylamino]-8-methyl-adenosine.  All these ligands have a 
substituent at the C8 position.  The substituent would favor a syn conformation of the 
adenine base in solution.  The inhibitors mentioned above also have a variety of 
terminal groups at the 5´ end to investigate the possibility of formation of a Schiff base 
to the active site pyruvoyl group.  The crystal structures revealed that a linker length 
of two carbon atoms between the central sulphur/nitrogen and the terminal group is 
ideal for the formation of a Schiff base.  The inhibition studies of these ligands suggest 
that the C8 substituted ligands were 5-18 times more potent than the unsubstituted 
parent compounds. 
In addition to the material discussed in chapters 2 - 5, complexes of 
AdoMetDC with 5´-deoxy-5´-[(2-aminooxyethyl)ethylamino]-adenosine, 5´-deoxy-5´-
[(2-hydrazinocarbonylethyl)methylamino]-8-adenosine, 5´-deoxy-5´-[(2-
carboxamidoethyl)amino]-adenosine, and 5´-deoxy-5´-[(2-
hydrazinocarbonylethyl)amino]-adenosine were also obtained (data not shown).  The 
latter two inhibitors do not have a third substituent on the central nitrogen atom but 
still maintain a positive charge at physiological pH for binding to AdoMetDC. 
Human AdoMetDC undergoes processing between residues Glu67 and Ser68 
to mature the active enzyme.  The S68A mutant prevents processing and traps the 
enzyme in the form of the proenzyme.  The crystal structure of the S68A mutant of 
AdoMetDC complexed to competitive inhibitors MMTA and DMAMA were obtained 
(data not shown).  The binding of the inhibitors induced a conformational change in 
the β turn containing the processing site.  The structural information could be used in 
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designing inhibitors to the proenzyme that block the autoprocessing reaction and 
hence block AdoMetDC activity.  
In addition to the inhibitor design of human AdoMetDC, the crystal structure 
of Thermotoga maritima AdoMetDC (TmAdoMetDC) in the processed form and 
complexed to MeAdoMet and MMTA were obtained.  The similarity between the 
prokaryotic and human enzyme suggests a case of evolution of the human enzyme by 
gene duplication and fusion.  In addition to the overall structure, the active site 
residues involved in autoprocessing and decarboxylation reactions in human 
AdoMetDC are also conserved in TbAdoMetDC.  The ligands MeAdoMet and 
MMTA bind to TbAdoMetDC in a similar pose as to the human enzyme and make 
similar interactions to the residues in the active site as in the human enzyme.  The 
comparison of the crystal structures of TbAdoMetDC and human AdoMetDC reveal 
recurring themes for substrate recognition and inhibitor design.  
 
 
 
